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Multiple classes of drugs, including antidepressants as well as opioid analgesics, exert their 
therapeutic effects at least in part by direct or indirect actions at G-protein-coupled receptors 
(GPCR’s).  This class of receptor propagates a signal inside the cell by activating heterotrimeric 
G-proteins (comprised of Gα and Gβγ subunits).  Following receptor activation GDP bound to 
the Gα subunit of the heterotrimer is exchanged for GTP, followed by separation of the Gα and 
Gβγ subunits.  Both Gα and Gβγ then activate downstream signaling pathways inside the cell. 
The regulator of G-protein signaling (RGS) proteins are a class of intracellular regulatory 
proteins that serve as negative modulators of GPCR signaling.  They exert their actions by 
binding to active Gα-GTP subunits and accelerating the hydrolysis of GTP to GDP with 
subsequent reformation of the Gα/βγ heterotrimer, thus terminating signaling.  
In this work, I describe the use of mice expressing Gα subunits of one of two types (either Gαi2 
or Gαo) that do not bind to RGS proteins and so are RGS insensitive (RGSi) to gain a better 
understanding of how RGS proteins regulate both antidepressant-like and antinociceptive 
behaviors.  Site-specific microinjections of a serotonin 1A receptor (5HT1AR) antagonist and 
agonist are used to show that mice expressing RGSi Gαi2 have a robust antidepressant-like 
phenotype dependent on hippocampal 5-HT1AR activity.  Ex vivo recording from hippocampal 
tissue confirms that a 5-HT1AR agonist inhibits cellular activity more effectively in mice 
expressing RGSi Gαi2.  Furthermore, I demonstrate that hippocampal administration of an 
RGS4/19 inhibitor (CCG203769) produces antidepressant-like effects.  I show that mice 
expressing RGSi Gαo have a complex phenotype including increased and decreased sensitivity to 
noxious stimuli consistent with alterations in both nociceptin receptor (NOPR) and mu opioid 
receptor (MOPR) activity.  The balance between the antinociceptive MOPR and pronociceptive 
NOPR systems is disturbed in the RGSi Gαo mice and in wild type mice during inflammatory 




with enhanced signaling downstream of different Gαi/o proteins due to the loss of RGS control, 
and provides novel information regarding the receptor systems and brain regions involved, with 
implications for both the treatment of depressive disorders and pain. This work is significant 
because it provides a greater understanding of the G-proteins involved in the perception of pain 









G-protein-coupled receptors (GPCRs) play an integral role in therapeutics as approximately 40% 
of all available prescription pharmaceuticals target GPCRs (Filmore 2004).  While there is 
considerable structural variability between GPCRs, this family of proteins exhibit a conserved 
heptahelical transmembrane structure (Lagerstrom and Schioth 2008) that leads to the alternate 
nomenclature ‘7-transmembrane domain receptors.’  The mu-opioid receptor (Fig. 0.1) is a 
typical example. There are over 800 GPCRs expressed in the human genome (Gloriam et al., 
2007), and drugs targeting these receptors are indicated for conditions including chronic pain, 
neuropsychiatric disorders, cancer and cardiac dysfunction among many others (Filmore 2004).  
Understanding the signaling processes that GPCRs regulate is therefore of critical importance not 
only for the development of new pharmaceuticals, but also to gain a better understanding of how 
Fig. 0.1: Ribbon diagram of the mu-opioid receptor 
crystal structure bound to a morphinan antagonist. 
Adapted with permission from Manglik et al., 2012. 
PDB ID: 4KDL 
Fig. 0.2: Ribbon diagram of RGS4 (top) in contact 
with Gαi1 (bottom) generated from a AlF4- 
stabilized crystal structure. 
From Tesmer et al., 1997. Reprinted with 




existing drugs that target GPCRs function.  The regulator of G-protein signaling (RGS) proteins 
(Fig. 0.2) are a family of intracellular regulatory proteins that have received increasing attention 
due to their ability to regulate GPCR activity (Fig. 0.3).  These proteins express a conserved 
RGS homology (RH) domain which provides the ability for RGS proteins to act as GTPase 
activating proteins (GAPs). This GAP activity allows RGS proteins to inhibit signaling 
downstream of GPCRs by facilitating the conversion of GTP to GDP in active Gα subunits.  
There is evidence that RGS proteins have selectivity for different Gα subunits (Table 0.1) and 
receptors.  The specifics of RGS protein regulation of GPCR signaling in relation to 
antidepressant action is discussed at length in chapter 1 and in relation to opioid analgesic action 
in chapter 3.     
 
The work presented in chapters 2 and 4 will describe the use of knock-in mouse models 
expressing modified Gα proteins that are insensitive to the negative modulatory effects of the 
RGS proteins.  These mouse models are used to explore the intracellular signaling processes 
downstream of the mu opioid (MOPR), nociceptin (NOPR) and serotonin 1A (5-HT1A) 
receptors that contribute to both antidepressant-like (chapter 2) and antinociceptive effects 
(chapter 4).  The loss of RGS control at these modified G-proteins depends on a glycine to serine 
Fig. 0.3: Depiction of GPCR cycle with regulation by RGS proteins.  RGS proteins 
interact with the active Gα subunit and facilitate its inactivation, allowing reformation of 
the heterotrimeric G-protein complex and association with the receptor, thereby 
terminating signaling. 





mutation at position 184 in either Gαi2 or Gαo.  The resulting gain of function G-protein variant 
are known as RGS insensitive (RGSi) G-proteins.  Further background on these RGSi G-proteins 
is provided in chapters 1 and 3. 
 
 
Table 0.1: RGS protein families, with conserved domains and G-protein specificity highlighted. 
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The Role of RGS and G-proteins in the Regulation of Depressive Disorders 
 
Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders with over 
16% of adults in the US experiencing a depressive event within their lifetime, and over half of 
these events leading to severe or very severe role impairment (García-Velázquez et al., 2017; 
Kessler et al., 2003).  While a multitude of antidepressant drugs are now available, no one 
treatment is fully effective in all patients, and any individuals fail to respond to even 2nd or 3rd 
line treatment options (Insel and Wang 2009).  This high rate of treatment failure combined with 
the high prevalence of depressive disorders demonstrates the need not only for improved 
treatment options, but also for a better understanding of the factors that determine whether a 
given treatment will succeed or fail. 
 
GPCRs in Depression 
The vast majority of drugs prescribed for depressive disorders either interact directly with G-
protein-coupled receptors (GPCRs) (e.g. buspirone with 5-HT1A or aripiprazole with a multitude 
of monoaminergic GPCRs) or indirectly regulate GPCR function by affecting endogenous 
neurotransmitter levels (e.g. selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine 
and monoamine oxidase inhibitors (MAOIs) such as selegiline; Kantor et al., 2015).  
Additionally, many GPCRs have been associated with the development of depression.  
Aberrations in both alpha- and beta-adrenergic receptor signaling have been found in depressed 
patients (Matussek et al., 1980; Ebstein et al., 1988) and the brains of suicide victims 
consistently have alterations in 5-HT1A receptor expression (and various nuclear receptors) 
resembling the alterations produced by chronic stress in animal models (Lopez et al., 1998). In 




results (see Stockmeier 2003 for review).  Nonetheless, a 5-HT2C receptor polymorphism in the 
N-terminal extracellular domain has been associated with MDD in a large population study 
(Lerer et al., 2001).  Preclinical models also implicate the 5-HT1B receptor both in the genesis of 
depressive states and in antidepressant action (Svenningsson et al., 2006).  Polymorphisms in 
both the dopamine D3 and D4 receptors have been correlated with the development of major 
depressive disorder (Dikeos et al., 1999; Lopez Leon et al., 2005), while D1 and D2 receptors 
have instead been linked to bipolar disorder (Dmitrzak-Weglarz et al., 2006; Massat et al., 
2002). Interestingly the GABA-B receptor agonist baclofen produces a transient depressive state 
in some patients (Post et al., 1991) suggesting this receptor may play a role in major depressive 
disorder.  A corticotropin-releasing hormone receptor 1 antagonist has also been found to have 
antidepressant activity (Zobel et al., 2000) in agreement with predictions from preclinical studies 
(Mansbach et al., 1997). 
In the inactive state GPCRs form a multi-protein complex with the intracellular α, β and γ type 
G-protein subunits (see Figure 0.1).  Following GPCR activation by endogenous 
neurotransmitters or exogenous agonists both the Gα subunit and the Gβγ complex will 
dissociate from the receptor and go on to stimulate or inhibit a range of intracellular effectors.  
The Gα activation process involves a loss of bound GDP (inactive form) in exchange for GTP 
(active form).  Signaling is terminated by the hydrolysis of the bound GTP back to GDP by the 
GTPase activity of the Gα subunit. A regulator of G-protein signaling (RGS) protein then binds 
to active Gα and facilitates its inactivation through an intrinsic GTPase accelerating protein 
(GAP) activity.  This enhances the Gα subunits’ innate GTPase activity, allowing the return to an 
inactive state through hydrolysis of Gα bound GTP.  The inactive GDP-bound Gα subunit can 
then recouple with both the receptor and Gβγ complex until the receptor is again activated and 
the cycle repeats.  For a review of GPCR signaling see Oldham and Hamm (2008). 
While this general process is well understood, determining specific RGS and G-proteins 
involved in antidepressant action may facilitate future antidepressant drug development.  
Furthermore, studying dysfunction of these systems in the depressed brain may provide insight 
into the etiology of depression.  Therefore, this chapter will highlight findings that provide 





G-Protein Subunits Involved in Depression and Antidepressant Action 
In preclinical studies, central nervous system (CNS) G-protein expression levels do not appear to 
change consistently as a result of antidepressant drug treatment.  Gαs, Gαo and Gαi mRNA 
expression in the rat hippocampus remained constant following chronic treatment with the 
tricyclic antidepressant imipramine (Lasoń et al., 1993).  Similarly, chronic treatment with the 
dual serotonin norepinephrine reuptake inhibitor (SNRI) amitriptyline, the tricyclic 
antidepressant desipramine, the MAOI tranylcypromine or electroconvulsive shock did not affect 
protein levels of Gαs, Gαo, Gαi or Gβ in the rat cerebral cortex (Chen and Rasenick 1995b; 
Emamghoreishi et al., 1996; Dwivedi and Pandey 1997).  In contrast, sub-chronic treatment with 
the MAOI antidepressant phenelzine increased Gαi2 protein expression in the rat cortex and 
hippocampus without affecting Gαs, Gαo, Gαq or Gαi1 expression in any brain region tested 
(Dwivedi and Pandey 1997) consistent with the involvement of Gαi2 in the actions of 
serotonergic antidepressants observed in mouse models (Talbot et al., 2010). However, this does 
not appear to be a conserved effect for all MAOI antidepressants on Gαi2, as chronic treatment 
with tranylcypromine did not affect cortical Gαi2 levels while chronic clorgiline instead produced 
a small decrease (Lesch et al., 1991; Emamghoreishi et al., 1996).  Three-week treatment with 
various tricyclic antidepressants (imipramine, desipramine, or chlomipramine) produced slight 
increases of brain Gαo and decreases of Gαs and Gαi, although the magnitude of these changes 
(~10-30% from baseline) may not be great enough to produce functional consequences (Lesch et 
al., 1991).  Furthermore, tricyclics such as desipramine and amitriptyline did not produce this 
effect in other studies (Chen and Rasenick 1995b; Emamghoreishi et al., 1996).   
A series of post-mortem studies examining the involvement of G-proteins in depressive states 
contrasts with the conclusions from pre-clinical studies discussed above.  Post-mortem studies 
indicate that a downregulation of Gαo and Gαi2 protein levels and mRNA co-occurs with an 
upregulation of Gαs protein levels and mRNA in the prefrontal cortex of adult suicide victims 
(Dwivedi et al., 2002).  However, only teenage subjects with a diagnosed history of mental 
illness showed such abnormalities with decreased mRNA for Gαo and Gαi2 and increased Gαs 
mRNA in the frontal cortex, without changes in protein levels (Dwivedi et al., 2002).  This fits 
with data from Gαi2 knock-out mice which show that loss of Gαi2 contributes to depressive 




may have contributed to their pathology.  Overall there is no consistent effect on G-protein 
expression in the brain following chronic antidepressant treatment, the effects that have been 
seen are not consistent between antidepressant drugs with similar pharmacology, and any 
changes that have been found are of relatively small magnitude. 
Despite the lack of any clear effect on G-protein expression levels, chronic but not acute 
antidepressant drug treatment (including amitriptyline, desipramine and iprindole) increases 
cAMP concentrations in a Gαs dependent manner in the rat brain, but not other tissues (Menkes 
et al., 1983; Ozawa and Rasenick 1989; De Montis et al., 1990).  In addition to antidepressant 
drug treatments, chronic electroconvulsive treatment increases coupling between Gαs and 
adenylyl cyclase in the brain but not peripheral tissues (Ozawa and Rasenick 1991).  In 
agreement with this increased cyclase activity, increased activity of cAMP dependent kinases 
have also been observed in the rat brain following chronic antidepressant treatment.  These 
changes occurred with chronic but not acute treatment with desmethylimipramine or fluoxetine, 
and were seen in the cerebral cortex but not hippocampus, striatum or cerebellum (Perez et al., 
1989).  This suggests a more general role for brain Gαs/adenylyl cyclase coupling in 
antidepressant action downstream of their better characterized direct effects on transporters and 
GPCRs. 
In order to understand how antidepressants affect G-protein signaling, it is necessary to consider 
not only the expression levels of these proteins and their binding partners, but also their 
subcellular localization in microdomains.  Within the plasma membrane bilayer there are lipid 
raft membrane microdomains which contain an increased proportion of both cholesterol and 
sphingomyelin (Simons et al., 2000).  G-proteins are known to accumulate in these lipid raft 
domains, with Gαs, Gαq and Gαi/o subunits all found at higher concentrations in these regions 
(Allen et al., 2005; Pesanová et al., 1999; Dunphy et al., 2001). These microdomains can affect 
G-protein dependent signaling, with either faciliatory or inhibitory effects on signaling 
depending on the G-protein.  For example, localization to raft regions inhibits the ability of Gαs 
proteins to increase cAMP levels through adenylyl cyclase activation while raft localization of 
Gαq greatly enhances signaling downstream of 5-HT2A receptor activation (Rybin et al., 2000; 
Bhatnagar et al., 2004; Ostrom and Insel 2004 for review).  In addition to an upregulation of Gαs 




depressed individuals.  Compared to non-
psychiatric control subjects there was 
approximately a two-fold increase in the 
localization of Gαs to lipid raft domains 
(see Figure 1.1; Donati et al., 2008). As 
these lipid raft domains are known to 
inhibit signaling downstream of Gαs, 
including coupling to adenylyl cyclase, this 
increased lipid raft localization likely 
indicates decreased Gαs signaling in the 
brain of depressed individuals as well 
(Head et al., 2006).  In fact, a Gαs 
dependent adenylyl cyclase dysfunction in 
the brains of suicide victims is supported 
by an impairment in the ability of forskolin 
to stimulate adenylyl cyclase activity in 
post-mortem tissue from individuals who 
committed suicide (Cowburn et al., 1994).  
This loss of cyclase activity is associated 
with decreased expression and activity of 
the cAMP dependent kinase (PKA) in the 
frontal cortex but not hippocampus of 
suicide victims (Pandey et al., 2005). 
Preclinical models suggest that antidepressants have both a stimulatory effect on adenylyl 
cyclase activity and reduce the amount of Gαs localized in lipid rafts (Toki et al., 1999; Donati 
and Rasenick 2005; Chen and Rasenick 1995a; Chen and Rasenick 1995b).  Both of these effects 
would in theory directly counteract changes detected in post-mortem brain tissue from suicide 
victims, namely impaired adenylyl cyclase activity and increased accumulation of Gαs in lipid 
rafts (Cowburn et al., 1994; Donati et al., 2008).  While these results predict that antidepressant 
treatment should correct these deficits observed in the depressed brain this hypothesis has not yet 
been fully tested. 
Fig. 1.1: Ratio of non-lipid raft vs. lipid-raft 
associated Gαs protein expression in post-mortem 
tissue from suicide victims vs. controls. The 
reduction in TTX-100/TTX-114 detergent soluble 
ratio indicates an increased accumulation of Gαs in 
lipid raft regions in the brains of suicide victims.   




In cellular models, multiple G-protein subtypes accumulate in lipid rafts and antidepressant drug 
treatment reduces the amount of lipid raft associated Gαs without changing the abundance of 
other G-proteins in the rafts (Toki et al., 1999; Donati and Rasenick 2005).  This reduction in 
lipid raft Gαs content occurs without changes in the overall expression level of Gαs protein, or in 
the expression of other G-proteins including Gαi, Gαo or Gβ (Chen and Rasenick 1995a).  The 
shift of Gαs from lipid raft regions to non-lipid raft regions coincides with increased coupling 
between Gαs and adenylyl cyclase as well as increased adenylyl cyclase activation and cAMP 
accumulation (Chen and Rasenick 1995a; Chen and Rasenick 1995b).  These effects occur with 
tricyclic antidepressants, SSRIs and atypical antidepressants suggesting a potential conserved 
antidepressant mechanism independent of primary site of action.   
Importantly the transfer of Gαs out of lipid raft domains occurs following chronic treatment with 
the antidepressant (S)-stereoisomer of the SSRI citalopram, but not the (R)-stereoisomer which 
lacks antidepressant effects (Zhang and Rasenick 2010).  This stereospecific effect of citalopram 
occurs in C6 cells lacking the serotonin transporter, suggesting that Gαs translocation out of lipid 
rafts occurs due to interaction of the antidepressant with some other protein target.  Furthermore, 
antidepressant drugs with diverse mechanisms of action (including desipramine, reboxetine and 
fluoxetine) themselves accumulate in these lipid raft domains over time (Eisensamer et al., 
2005).  While together these data suggest that a specific binding site for antidepressants within 
lipid rafts may exist, a suitable candidate site has yet to be identified.  
Therefore, in general antidepressant drugs liberate Gαs from the inhibitory effects of lipid raft 
localization allowing this subunit to signal more effectively through downstream effectors 
including adenylyl cyclase (Head et al., 2006).  These effects are specific to the brain as 
peripheral tissues do not show the same response, and even within the brain there is regional 
specificity as brain regions other than the cerebral cortex show reduced Gαs translocation if any 
(Dwivedi et al., 2002).  This provides a plausible mechanism for the long-recognized ability of 
antidepressant drugs to increase the coupling between Gαs and adenylyl cyclase (Menkes et al., 
1983).  Importantly this enhancement occurs only following extended antidepressant treatment, 
consistent with the hysteresis observed between the initiation of antidepressant treatment and the 




Multiple serotonin receptors likely contribute to the antidepressant effects of serotonergic 
antidepressants; however, a wealth of data suggests that the 5-HT1A receptor plays an important 
role.  5-HT1A is a typical Gαi/o coupled receptor, and many lines of evidence suggest it couples 
to Gαi3 and Gαi2 with considerable selectivity compared to Gαi1 and Gαo (Bertin et al., 1992; 
Clawges et al., 1997; Garnovskaya et al., 1997).  Unfortunately, all of these studies used the 
prototypical 5-HT1A agonist 8-OH-DPAT, while other agonists at this receptor may have 
distinct selectivity profiles of receptor/G-protein coupling.  This agonist-dependent G-protein 
selectivity has been shown at other receptors including the D2 dopamine receptor and the M1 
muscarinic acetylcholine receptor among others (Masuho et al., 2015; Melancon et al., 2013) 
and reveals a potential advantage of drugs that interact directly with receptors instead of 
indirectly modulating neurotransmitter levels such as the SSRIs.  Regardless of which SSRI is 
employed, the therapeutic effects arise from serotonin interacting with serotonin receptors, 
precluding the possibility for an agonist-dependent G-protein selectivity.  While some direct 5-
HT1A agonists such as buspirone show promise for treating depression, a detailed analysis of G-
protein selectivity for these agonists has not been performed. 
Mice lacking Gαi2 exhibit a spontaneous pro-depressant phenotype (Talbot et al., 2010).  
Conversely mice expressing a gain of function knock-in variant of Gαi2 exhibit spontaneous 
antidepressant-like behaviors (Talbot et al., 2010).  As these behaviors are reversible by 
pretreatment with a 5-HT1A antagonist this suggests that signaling through the 5-HT1A/Gαi2 
signaling complex promotes antidepressant-like effects while disruption of this complex may 
contribute to depressive behaviors. Therefore, disruption of Gαi2, either due to genetic variation 
or by other means, may have detrimental neuropsychiatric effects. Conversely 5-HT1A agonists 
with preference for Gαi2 signaling compared to other Gαi/o proteins could have superior effects 
compared to a 5-HT1A agonist without G-protein selectivity. 
Together these data suggest a dysregulation of G-protein signaling in the brains of depressed 
individuals.  The dysregulation likely involves changes in overall G-protein expression, as well 
as translocation of Gαs into a more restrictive membrane microenvironment where signaling to 
downstream effectors is inhibited, with apparent consequences for cyclase dependent signaling 
pathways including PKA.  It remains unclear whether these changes contribute to suicidal 




causative effect.  In either case the existence of these changes may allow for new strategies to 
diagnose and potentially treat depressive disorders. 
 
RGS Protein Regulation of G-protein Activity 
RGS proteins (see Table 0.1 for general information on these proteins) have some degree of 
specificity for which Gα subunits they can regulate.  For example, RGS4 and RGS8 potently 
inhibit signaling downstream of Gαi2 in vitro while RGS7 has no effect (Talbot et al., 2009).  
RGS-PX1 exclusively regulates signaling downstream of Gαs (Zheng et al., 2001), while RGS2 
preferentially modulates Gαq signaling (Heximer et al., 1997).  RGS proteins also appear to have 
specificity in terms of which GPCRs they regulate, even when those GPCRs signal through the 
same type of G-proteins.  The dopamine D2 receptor and 5-HT1A receptors are both Gαi/o 
coupled GPCRs, however RGS4, RGS10 and RGSZ1 reduced 5-HT1A-mediated signaling in 
vitro but did not affect D2-mediated signaling (Ghavami et al., 2003).  It remains unclear 
whether RGS proteins achieve this specificity through direct interaction with certain GPCRs or 
by interactions with other intracellular binding partners.  This level of specificity has been 
studied more thoroughly with RGS/opioid receptor interactions and is discussed further in 
chapter 3. 
Membrane anchoring can also affect how RGS proteins regulate G-protein action.  For example, 
the loss of two available palmitoylation sites on RGS16 can prevent it from negatively regulating 
Gαi and Gαq signaling (Hiol et al., 2003).  RGS proteins in complex with a Gα subunit can also 
directly affect signaling to downstream effectors, independent of the RGS GAP function.  This 
level of regulation also depends on the specific RGS protein involved, for instance RGS2 in 
complex with Gαq can prevent Gαq from binding to the downstream effectors p63 RhoGEF and 
GRK2, while RGS4 in complex with Gαq has little effect on binding to these effectors 
(Shankaranarayanan et al., 2008).  
Therefore, while different RGS proteins have classically been thought of as having largely 
redundant actions, current evidence suggests that different family members have considerable 




downstream effectors.  This highlights the need for a better understanding of what role the RGS 
proteins play in neuropsychiatric disorders and treatments. 
 
RGS Proteins Involved in Depression and Antidepressant Action 
RGS2 
Changes in individual RGS protein expression may have the potential to produce pro-depressant 
effects.  For example, mice lacking RGS2 showed a baseline increase in anxious and depressive-
like behaviors (Lifschytz et al., 2012; Oliveira-dos-Sanos et al., 2000).  These behavioral 
alterations occurred alongside decreased raphe 5-HT1A receptor expression and function 
suggesting that these receptors may play a role in the observed behavioral phenotype (Lifschytz 
et al., 2012).  In contrast, a genetic manipulation which specifically increases raphe 5-HT1A 
expression in mice increases vulnerability to stress and decreases response to antidepressants 
(Richardson-Jones et al., 2010), suggesting that reductions in raphe 5-HT1A following 
disruption of RGS2 may be a compensatory change rather than a causative factor of the pro-
depressant behaviors.  Nonetheless, these data demonstrate that RGS2 may have a protective 
effect against anxiety and depression, and that RGS2 disruption may have detrimental 
neuropsychiatric effects. 
In line with these pre-clinical results, individuals expressing any of several single nucleotide 
polymorphisms (SNPs) in the RGS2 gene experience anxiety disorders and suicidal ideations at 
an increased rate (Amstadter et al., 2009; Leygraf et al., 2006; Smoller et al., 2008).  In addition, 
an increase in RGS2 immunoreactivity was found in post-mortem tissue from both the prefrontal 
cortex and amygdala of individuals who committed suicide (Cui et al., 2008).  Together these 
findings provide solid evidence that genetic alterations in the RGS2 gene can influence the 
development or expression of affective disorders in human populations, in line with findings 
from RGS2 knockout mice. 
While it remains difficult to study antidepressant action in vitro, a number of studies have 
provided evidence on how RGS2 can affect cellular processes in ways that could modify 
antidepressant action.  An increase in hippocampal synaptic plasticity typically occurs following 




Nissen et al., 2010).  Loss of RGS2 produces a similar loss of synaptic plasticity in mouse 
hippocampal tissue potentially by altering Gαi/o-mediated inhibition of hippocampal Ca
2+ 
channels (Han et al., 2006).  This suggests that a loss of neural plasticity due to genetic variation 
in RGS2 could have detrimental neuropsychiatric effects and might impair the function of 
antidepressant drugs.  
RGS4 
Studies in rodent models have consistently shown that 5-HT1A agonists such as 8-OH-DPAT 
cause a reduction in extracellular serotonin levels in the brain by activating 5-HT1A 
autoreceptors in the dorsal raphe nucleus (DRN) (Casanovas and Artigas 1996; Adell and 
Artigas 1998; Celada et al., 2001).  It is thought that this 5-HT1A dependent reduction in central 
serotonin levels may delay the beneficial effects of SSRI antidepressants, and strategies to limit 
5-HT1A autoreceptor activity during SSRI treatment, such as co-administration of 5-HT1A 
antagonists or weak partial agonists, have shown promising results (Artigas et al., 1994; Perez et 
al., 1997; Tome et al., 1997; Maes et al., 1999). Although RGS4 mRNA is not normally 
expressed in the DRN (Gold et al., 1997), RGS4 overexpression in the DRN attenuates the 
ability of 5-HT1A receptors to reduce central serotonin levels (Beyer et al., 2004).  Based on 
these results, overexpression of RGS4 in brain regions containing 5-HT1A autoreceptors should 
have beneficial effects on antidepressant drug action, similar to the results obtained by 
combining 5-HT1A antagonists with traditional antidepressants (Artigas et al., 1994).   
Delta opioid receptor (DOPR) agonists produce antidepressant-like behavioral effects in rodent 
models including the tail suspension and forced swim tests (Broom et al., 2002; Naidu et al., 
2007).  RGS4 knockout mice show an enhanced antidepressant-like response to DOPR agonists 
in the forced swim test, but not tail suspension test, suggesting that these antidepressant-like 
behaviors may depend on distinct signaling intermediates downstream of DOPR activation 
(Stratinaki et al., 2013; Dripps et al., 2017).  This effect on forced swim test behavior appears to 
depend on nucleus accumbens RGS4 expression, as specific RGS4 knockdown in this region 
produces similar effects as global RGS4 knockout (Stratinaki et al., 2013).  RGS proteins 
capable of modulating DOPR-mediated tail suspension test behavior have not yet been 




In addition to inhibiting the antidepressant-like effects of DOPR agonists, loss of RGS4 appears 
to inhibit the antidepressant-like effects of SSRIs, norepinephrine reuptake inhibitors and the N-
methyl-D-aspartate (NMDA) receptor antagonist ketamine as well (Stratinaki et al., 2013).  
Acute treatment with either a DOPR agonist or ketamine decreases frontal cortex RGS4 
expression yet only chronic treatment with a DOPR agonist increases RGS4 expression in the 
nucleus accumbens (Stratinaki et al., 2013).  While this would suggest that nucleus accumbens 
and frontal cortex RGS4 may have opposing effects on antidepressant action, this has yet to be 
conclusively demonstrated. 
Although RGS4 expression in the brain does not appear to differ between post-mortem tissue 
from depressed and healthy individual, an upregulation of RGS4 has been observed in post-
mortem nucleus accumbens tissue from depressed individuals undergoing antidepressant 
treatment compared to untreated depressed individuals (Stratinaki et al., 2013).  Coupled with 
findings from rodent models showing increased antidepressant effectiveness in animals with 
overexpression of RGS4 in this brain region, it appears possible that nucleus accumbens RGS4 
has a facilitatory effect on antidepressant treatment. 
RGS6 
Mice lacking RGS6 display antidepressant-like and anxiolytic behaviors at baseline, including in 
the elevated plus maze and novelty induced hyponeophagia test (Stewart et al., 2014).  This 
behavioral phenotype is fully reversible by 5-HT1A antagonist pretreatment, and by direct 
activation of adenylyl cyclase with forskolin (Stewart et al., 2014). Loss of RGS6 did not affect 
mitogen-activated protein kinase (MAPK) or glycogen synthase kinase 3 beta (GSK3β) signaling 
(Stewart et al., 2014), changes that have been detected in mice with a 5-HT1A dependent 
antidepressant-like phenotype due to loss of RGS control at Gαi2 (Talbot et al., 2010).  Instead 
the RGS6 knockout mouse phenotype appears to depend on increased phospho-CREB in the 
hippocampus and cortex, areas with high 5-HT1A receptor expression (Stewart et al., 2006).  
These findings suggest that RGS6 may normally limit the actions of serotonergic antidepressants 
by reducing adenylyl cyclase inhibition downstream of 5-HT1A receptor activation, and that 






Palmitoylation causes the accumulation of RGS16 in lipid raft domains, a subcellular membrane 
compartment known to generally promote signaling downstream of Gαq, which RGS16 regulates 
(Rybin et al., 2000; Hiol et al., 2003).  This localization places RGS16 at or near a putative, but 
not yet positively identified binding site for antidepressant drugs within lipid rafts, as discussed 
earlier (Eisensamer et al., 2005).  This localization may provide RGS16 with an increased ability 
to regulate antidepressant drug action, although this prediction has yet to be tested. 
RGS19 
RGS19 has been shown to regulate 5-HT1A signaling in both C6 and SH-SY5Y cells (Wang et 
al., 2014), while RGS4 knockdown did not significantly affect signaling.  RGS19 knockdown 
facilitated 5-HT1A agonist induced activation of MAPK and inhibition of adenylyl cyclase 
(Wang et al., 2014).  The effect of RGS19 knockdown was magnified when the cells were co-
treated with fibroblast growth factor 2 (FGF2), a factor known to act synergistically with 5-
HT1A receptor activity in the hippocampus to facilitate synaptic plasticity (Wang et al., 2014; 
Borroto-Escuela et al., 2012).  The enhancement of 5-HT1A agonist stimulated MAPK activity 
following RGS19 knockdown seen in cellular models was replicated in mouse primary 
hippocampal neurons, including the synergistic enhancement by co-treatment with FGF2 and a 
5-HT1A receptor agonist (Wang et al., 2014).  This suggests that reducing RGS19 activity may 
facilitate the action of serotonergic antidepressants due to disinhibition of hippocampal 5-HT1A 
receptor activity. 
 RGSZ1  
Chronic estradiol treatments both desensitize hypothalamic 5-HT1A receptors and cause an 
increase in RGSZ1 expression (Carrasco et al., 2004).  Increased RGSZ1 would be expected to 
reduce signaling downstream of 5-HT1A and may therefore contribute to the observed 5-HT1A 
receptor desensitization, although this interaction has not been conclusively demonstrated 
(Carrasco et al., 2004).  5-HT1A receptor desensitization in the DRN, not the hypothalamus, is 
generally considered a critical step in antidepressant action.  However, RGSZ1 expression in the 
DRN has not been assessed following chronic antidepressant treatment, so it remains possible 




RGS Insensitive G-Proteins 
When an individual RGS protein is knocked out or genetically modified, other available RGS 
proteins can at least partially compensate.  Similarly, when a G-protein is lost a GPCR may be 
able to continue signaling through other available G-proteins.  In order to overcome these 
difficulties a series of modified G-proteins were developed which are totally insensitive to the 
negative regulatory effects of RGS proteins. 
The first known RGS insensitive (RGSi) G-
protein was found in a strain of 
saccharomyces cerevisiae yeast as a 
naturally occurring allele of the endogenous 
Gα protein subunit (DiBello et al., 1998).  
This mutant G-protein was insensitive to 
the negative regulatory effects of RGS 
proteins, although its signaling was not 
altered otherwise (DiBello et al., 1998).  
This profound loss of RGS sensitivity 
occurred due to a single missense mutation 
(gly-to-ser at position 302) in the switch 1 
region of the Gα subunit.  This glycine is 
conserved across Gα subtypes and is 
located in a region where RGS proteins and 
G-protein make direct contact (see Figure 
0.2; Tesmer et al., 1997).   
The potential utility of this RGSi G-protein was quickly recognized and a series of novel 
mammalian RGSi G-proteins were created including Gαo, Gαi1, and Gαq among others (DiBello 
et al., 1998; Lan et al., 1998).  Like the originally identified yeast RGSi G-protein these 
mutations did not affect the kinetics of GDP release, GTP hydrolysis, Gβγ binding, or interaction 
with the receptor, but produced up to 100-fold loss of affinity for RGS proteins (Day et al., 2004; 
Fu et al., 2004).  These properties allowed investigators to probe the effects of removing all RGS 
Fig. 1.2: Antidepressant-like phenotype of heterozygous 
(GS/+) and homozygous (GS/GS) RGS insensitive Gαi2 
knock-in mice compared to wild type (+/+) littermates.  
Pretreatment with the 5-HT1A receptor antagonist WAY-
100635 reversed this behavior to wild type levels. 




control at a specific G-protein without affecting G-protein signaling otherwise, avoiding the 
difficulties posed by RGS protein redundancy.   
Mice expressing an RGSi knock-in variant of Gαi2 display a profound antidepressant-like 
phenotype across a number of behavioral tests including tail suspension, forced swim, elevated 
plus maze and novelty induced hypophagia (see Figure 1.2; Talbot et al., 2010).  These mice also 
have antidepressant-like signaling changes in the hippocampus and frontal cortex, including an 
inhibition of GSK3β activity (Talbot et al., 2010).  GSK3β inhibition produces neurogenesis in 
the adult hippocampus, and this neurogenic effect may be a critical component of antidepressant 
action (Malberg et al., 2000; Li et al., 2004; Tsai et al., 2008).  
Both the changes in hippocampal GSK3β and antidepressant-like behaviors observed in RGSi 
Gαi2 knock-in mice are fully reversed by pretreatment with a 5-HT1A antagonist (Talbot et al., 
2010).  Coupled with the fact that 5-HT1A agonists produce more potent antidepressant-like 
effects in these animals, it appears that the loss of RGS control at Gαi2 promotes 5-HT1A 
receptor signaling leading to robust antidepressant-like effects.   
Although activating post-synaptic 5-HT1A heteroreceptors is generally considered beneficial for 
antidepressant action, pre-synaptic 5-HT1A autoreceptor activation can limit antidepressant 
action and may contribute to the hysteresis observed between initiation of treatment and the 
onset of therapeutic effects (Artigas et al., 1994; Hjorth and Sharp 1993; Le Poul et al., 1995; 
Matsuda et al., 1995).  Interestingly RGSi Gαi2 knock-in mice display enhancements of 
responses known to depend on 5-HT1A heteroreceptor activity (e.g. antidepressant-like 
behaviors, hippocampal GSK3β inhibition) but not responses dependent on 5-HT1A autoreceptor 
activity (e.g. hypothermia; Hillegaart 1991; Matsuda et al., 1995; Li et al., 2004; Talbot et al., 
2010).  This suggests that disrupting RGS control of Gαi2 may represent a novel strategy to 
selectively enhance the antidepressant effects of 5-HT1A receptor activation without promoting 
the detrimental effects of autoreceptor activation.   
Unfortunately, specific RGS proteins involved in the RGSi Gαi2 antidepressant-like phenotype 
are not currently known. While RGS19 has received attention for its ability to strongly regulate 
5-HT1A receptor function in vitro, it remains unclear whether this effect involves Gαi2 or 
another Gαi/o protein (Wang et al., 2014).  RGS6 has also been proposed as a possible mediator 




knock-out mice, including a 5-HT1A reversible antidepressant-like phenotype (Stewart et al., 
2014).  Substantial mechanistic differences exist between these mouse models however, 
including a lack of 5-HT1A reversible GSK3β inhibition in RGS6 knock-out mice.  This calls 
into question whether RGS6 is the primary mediator of the RGSi Gαi2 mouse phenotype, 
although it may be one of several RGS proteins involved.  
 
Conclusions 
RGS and G-proteins likely play important roles in the development of depressive states, and also 
influence the effectiveness of antidepressant therapies.  Changes in expression level of these 
proteins can have dramatic effects on these complex disorders, while even more subtle 
alterations (such as G-protein translocation between subcellular microdomains) can profoundly 
regulate antidepressant action.  Although preclinical studies provide a plethora of hypotheses for 
how these proteins behave in depressed populations in the clinic, only a handful of these theories 
have been adequately explored at the patient level.  Considering how alterations in RGS or G-
proteins differentially affect responses to different antidepressant treatments, it appears 
reasonable that a better understanding of these proteins could aid in the tailoring of personalized 
treatment strategies for depressed individuals.  Screening for changes in RGS or G-proteins 
could also provide new insight into susceptibility towards depressive disorders at an individual 
level.  In addition, direct RGS-inhibiting compounds have been proposed as novel treatment 
options for a variety of indications, and selective small molecule RGS inhibitors have already 
been identified (Zhong and Neubig 2001; reviewed in Roman et al., 2007).  A more complete 
understanding of how these families of proteins interact with antidepressant therapies and the 
development of depressive states is therefore badly needed.   
The following chapter will build on the work described here by testing the hypothesis that the 5-
HT1A receptor in the hippocampus is the key driver of the antidepressant-like phenotype in the 
RGSi Gαi2 knock-in mouse.  Studies using intra-hippocampal delivery of an RGS4/19 inhibitor 
(CCG-203769) to produce antidepressant-like effects are also highlighted.  This work will allow 
a greater understanding of how RGS proteins can be modulated to produce antidepressant-like 
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Loss of RGS Control at Gαi2 Produces Antidepressant-Like Behavior by an Action at 5-
HT1A Receptors in the Hippocampus 
 
Abstract 
A single base mutation in the Gαi2 protein (G184S) renders this Gα subunit insensitive to the 
negative modulatory effects of regulator of G-protein signaling (RGS) proteins.  Mice expressing 
this RGS insensitive (RGSi) variant of Gαi2 (RGSi Gαi2) display a spontaneous antidepressant-
like phenotype that is reversible by pretreatment with the 5-HT1A receptor (5-HT1AR) 
antagonist WAY100635.  Here we test the hypothesis that increased activity of 5-HT1ARs in the 
hippocampus of RGSi Gαi2 knock-in mice is responsible for the expression of the observed 
antidepressant-like behavior. We administered the 5-HT1AR antagonist WAY100635 or the 
agonist 8-OH-DPAT via bilateral intra-hippocampal infusion cannulae and tested for 
antidepressant-like behavior using the tail suspension test (TST). WAY100635 reversed the 
antidepressant-like phenotype of the RGSi Gαi2 knock-in mice and 8-OH-DPAT produced an 
antidepressant-like response in wild type mice that was blocked by systemic WAY100635.  
Furthermore, intra-hippocampal infusion of the RGS4/19 inhibitor CCG-203769 produced an 
antidepressant-like effect in female mice.  Ex-vivo slice recording confirmed an enhancement of 
the 5-HT1AR-mediated decrease in hippocampal CA1 pyramidal neuron excitability of the RGSi 
Gαi2 knock-in mice.  There was no change in hippocampal 5-HT1AR expression as measured by 
ligand binding or in the ability of 8-OH-DPAT to activate G-protein as measured in the 
[35S]GTPγS assay.  These findings suggest that RGS proteins highly expressed in the 







Although selective serotonin reuptake inhibitors (SSRIs) are widely used in psychiatric 
treatments, this class of drugs suffers from serious drawbacks including limited clinical efficacy 
and a long delay between the initiation of treatment and the onset of therapeutic effects.  This lag 
period is thought to be caused by the need to activate and subsequently desensitize serotonin 1A 
(5-HT1A) autoreceptors located predominantly in the raphe nucleus (Hjorth et al., 2000).  
However, a substantial body of research has identified 5-HT1A receptors (5-HT1ARs) on 
postsynaptic sites (i.e. heteroreceptors) in the frontal cortex and hippocampus as potential 
mediators of the beneficial effects of serotonergic antidepressants (Celada et al., 2013). The 
involvement of 5-HT1ARs in both the therapeutic and negative effects of SSRIs has hindered the 
development of antidepressant therapies which maintain the beneficial effects of SSRIs while 
avoiding their drawbacks.  
The 5-HT1AR is a typical 7-transmembrane domain G-protein-coupled receptor (GPCR) with 
high expression throughout the brain (Ito et al., 1999).  The 5-HT1AR couples to heterotrimeric 
Gαi/o proteins comprised of Gα and βγ subunits and as such its signaling is moderated by the 
regulators of G-protein signaling (RGS) proteins (Beyer et al., 2004; Ghavami et al., 2004; 
Wang et al., 2014).  RGS proteins are a family of intracellular proteins that regulate G-protein 
function by directly interacting with and inactivating heterotrimeric G-proteins (Berman et al., 
1996).  RGS proteins have GTPase accelerating activity which promotes the hydrolysis of active 
Gα-GTP to form inactive Gα-GDP.  This allows for reformation of the inactive heterotrimer, 
thus halting the downstream signaling activity of both the Gα and βγ subunits (see Fig 0.3; 
Stewart et al., 2012).   
The high degree of functional redundancy between individual RGS proteins has often provided a 
significant hurdle to understanding the specific function of individual RGS proteins (Dong et al., 
2000; Doupnik et al., 2001; Chen et al., 2010).  In order to overcome this issue a series of RGS 
insensitive (RGSi) Gα protein variants have been developed (Lan et al., 1998; Huang et al., 
2006).  These mutant Gα proteins have a single base mutation (Gly to Ser) at the site where RGS 
proteins normally interact with the Gα subunit (see Figure 0.2; Tesmer et al., 1997). For Gαi2 this 
is Gly184.  The mutation prevents interaction of the Gα protein with all RGS proteins while 




et al., 2004; Clark et al., 2003) and so provides the opportunity to determine the effect of 
removing RGS control of a specific Gα protein. 
Homozygous mice expressing the RGSi Gαi2 protein (Gαi2 
GS/GS) display a baseline 
antidepressant-like phenotype which is fully reversible by 5-HT1AR antagonist pretreatment 
(Talbot et al., 2010), suggesting an important role for Gαi2 and RGS proteins downstream of the 
5-HT1AR.  However, only a subset of 5-HT1AR dependent effects appear to be enhanced in 
these mice.  Hypothermia, an effect traditionally associated with 5-HT1A autoreceptor 
activation, is not affected by the mutation suggesting that 5-HT1A heteroreceptors may be the 
important mediators of the behavioral phenotype.  Identifying the brain locus responsible for the 
antidepressant-like phenotype in the Gαi2 
GS/GS mice would be an important step forward and 
allow us to study individual RGS proteins expressed in this region of the brain that regulate Gαi2 
downstream of the 5-HT1AR. 
The hippocampus and frontal cortex of the Gαi2 
GS/GS mice have increased levels of the Ser-9 
phosphorylated version of glycogen synthase kinase-3 beta (GSK3β), although pretreatment with 
the 5-HT1AR antagonist WAY100635 reverses this change fully only in the hippocampus 
(Talbot et al., 2010).  GSK3β is a neurogenic factor that is phosphorylated by antidepressant 
drugs and may contribute to their therapeutic effects (Malberg et al., 2000; Tsai et al., 2008).  
The 5-HT1A antagonist reversible increase of hippocampal phospho-GSK3β in the Gαi2 
GS/GS 
mice suggests the hippocampus as a potential critical site of their 5-HT1AR dependent 
antidepressant-like behavior. To test this hypothesis, we delivered drugs directly to the 
hippocampus and measured antidepressant-like behavior using the tail suspension test (TST).  
We find that hippocampal microinjection of a 5-HT1AR antagonist fully reverses the Gαi2 
GS/GS 
antidepressant-like phenotype, while hippocampal injection of a 5-HT1AR agonist to wild type 
animals produces effects consistent with the RGSi Gαi2 
GS/GS behavioral phenotype.  We also 
show that 5-HT1AR agonists have enhanced inhibitory effects on the intrinsic excitability of 
CA1 hippocampal neurons from heterozygous Gαi2 
+/GS mice. There are no observed changes in 
5-HT1AR density in the hippocampus of the RGSi Gαi2 knock-in mice, suggesting that the 
phenotypic differences occur due to signaling changes downstream of the receptor.   Finally, we 
demonstrate that inhibiting an RGS protein highly expressed in the hippocampus can produce an 




Materials and Methods 
RGSi Gαi2 knock-in mice.  Wild type (Gαi2 
+/+), heterozygous (Gαi2 
+/GS) and homozygous (Gαi2 
GS/GS) RGSi Gαi2 knock-in mice were derived from heterozygous breeding as described 
previously (Huang et al., 2006).  Animals were backcrossed onto the C57BL/6J background 
strain for four generations before heterozygous breeding.   
RGSi Gαo knock-in mice. Wild type (+/+) and heterozygous (+/GS) RGSi Gαo knock-in mice 
were generated as described previously on a 129S1/SvIMJ background strain (Fu et al., 2004; Fu 
et al., 2006; Huang et al., 2006; Goldenstein et al., 2009). As mice on the 129S1/SvIMJ 
background typically produce small, inconsistent litters (unpublished observation), heterozygous 
female RGSi Gαo knock-in mice on a 129S1/SvIMJ were bred with male wild type C57BL/6J 
mice.  The resulting F1 C57/129 cross were used for experiments involving RGSi Gαo.   
All animals were between 8 and 16 wk of age at time of testing, and animals were age and sex 
matched in each experiment.  In experiments where sex is not specified a pilot experiment was 
performed to identify potential sex differences.  If no difference was observed in this pilot then 
results from male and female animals were pooled in further experiments.  Mice were group 
housed with up to five same-sex littermates per cage.  The vivarium was maintained on a 12 hr 
light/dark cycle with lights on at 7:00 AM.  All testing occurred during the light phase.  Drugs 
were typically administered i.p. 30 min before testing unless otherwise indicated.  All 
experimental procedures were approved by the local Institutional Animal Care and Use 
Committee and followed the National Institute of Health guidelines outlined in “Using Animals 
in Intramural Research.” 
Tail suspension test. A piece of adhesive tape was affixed to the distal end of the mouse’ tail 
and attached to a metal bar elevated 30 cm above the table surface (Steru et al., 1985).  Behavior 
was recorded for 6 min and later scored for immobility time.  Immobility was defined as any 
period without continuous movement.  Isolated head movements, and swinging without other 
movement were also defined as immobile. 
Intra-hippocampal cannulation.  Mice were anesthetized with a combination of ketamine (100 
mg/kg i.p.) and xylazine (10 mg/kg i.p.).  Carprofen (5 mg/kg s.c.) was administered before and 




Model 902 Dual Small Animal Stereotaxic Instrument) and a midline incision made over the top 
of the skull.  Bregma and lambda were located and marked to determine implant position.  
Bilateral implant coordinates were 1.5 mm posterior, 1.0 mm ventral and 1.0 mm distal from the 
midline on each side.  Bilateral guide cannulae (C235GS-5-2.0/SPC) were custom ordered from 
Plastics One Inc. with a center-to-center distance of 2.0mm between each cannula and 2.0 mm 
cannula cut length.  To prevent blockage within the guide cannula a bilateral dummy cannula 
was kept in the guide cannula at all times following surgery except during intra-hippocampal 
infusions.  Animals were allowed to recover for at least seven days following surgery before any 
experimental testing took place.  Any animals that showed signs of distress during this recovery 
period were removed from the experiment and euthanized.  Following experimental testing a 
solution containing Fast Green FCF dye was infused through the cannula.  Brains were then 
dissected and rapidly frozen before sectioning.  When staining indicated a misplaced cannula, 
data from this animal were excluded from the experiment.    
Intra-hippocampal infusions.  Immediately before infusion animals were placed in a drop jar 
containing isoflurane and breathing was monitored until rate reached approximately one breath 
per second.  A bilateral injection cannula attached by flexible plastic tubing to two Hamilton 
syringes (Hamilton #86274 syringe) was then inserted through the guide cannula.  A 500 nl 
infusion was then delivered to each side at a rate of 250 nl per min using a syringe pump.  
Following infusion, the injection cannula remained in place for a further two min to prevent 
backflow away from the infusion site.  Drugs were administered 30 min before testing unless 
otherwise indicated.  For experiments involving repeated intra-hippocampal infusions this 
process was repeated once every 24 hr for three days, and experimentation occurred 30 min after 
the final infusion. 
Drugs.  (R)-(+)-8-OH-DPAT hydrobromide ((R)-(+)-2-dipropylamino-8-hydroxy-1,2,3,4-
tetrahydronaphthalene hydrobromide) and WAY100635 maleate salt (N-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate salt) were 
purchased from Sigma-Aldrich Co. LLC.  CCG-203769 was generously donated by the lab of 
Dr. Richard Neubig.  
Ex-vivo hippocampal cell recordings.  Whole cell patch clamp recordings of hippocampal CA1 




Mice were anesthetized with isoflurane and brains were rapidly removed and placed in ice-cold 
oxygenated (95% O2-5% CO2) artificial cerebrospinal fluid (aCSF) containing (in mM): 200 
sucrose, 25 NaHCO3, 12.5 glucose, 1.25 NaH2PO4, 3.5 KCl, 1L-ascorbic acid, 0.5 CaCl2, 3 
MgCl2, 305 mOsm, pH 7.4. Coronal slices (300 μm) containing the hippocampus were made 
using a Leica VT1200 vibratory microtome (Leica Biosystems, Buffalo Grove, IL, USA) and 
allowed to rest in oxygenated aCSF for at least 40 min before recording. For the recording aCSF, 
CaCl2 was increased to 2.5 mM and MgCl2 was decreased to 1 mM. Patch pipettes were pulled 
from 1.5 mm borosilicate glass capillaries (WPI, Sarasota, FL) to a resistance of 3–7 MΩ with a 
horizontal puller (Model P97, Sutter Instruments, Novato, CA, USA) and filled with a solution 
containing (in mM): 130 K-methanesulfonate, 10 KCl, 0.4 EGTA, 2 MgCl2, 2 Mg
2+-ATP, 0.25 
Na3+-GTP, and 10 HEPES, pH 7.3, 285 mOsm when performing current clamp experiments. 
CA1 hippocampal neurons were identified based on their response to current injection (−200 to 
140 pA, 10 pA increments, 500 ms). Neuronal excitability was determined by measuring the 
number of action potentials elicited by each depolarizing current injection. Input resistance (IR) 
was determined by the change in voltage from 0 pA to -170 pA current injections. Rheobase is 
defined as the minimum amount of current injection to elicit an action potential.  
Hippocampal membrane preparation for binding assays.  Immediately before tissue 
preparation mice were sacrificed by cervical dislocation followed by decapitation and the brain 
was removed.  The hippocampus was then microdissected and isolated. The hippocampi from 6-
8 mice matched for age, gender and genotype were pooled to obtain enough tissue for 
experiment.  Hippocampi were homogenized in ice cold 50 mM tris buffer pH 7.4 then prepared 
as described previously (Lester and Traynor 2006).   Protein concentration was then determined 
with a BCA assay kit (Thermo Scientific, Rockford, IL). 
[3H]8-OH-DPAT saturation binding assay. Membrane homogenates containing hippocampal 
tissue (100 μg/well) were incubated in 50 mM pH 7.4 Tris buffer with [3H]8-OH-DPAT ranging 
in concentration from 0.156 nM up to 20 nM increasing in 2-fold steps.  Non-specific binding 
was determined at each point with the addition of 10 μM WAY-100635.  Each condition was 
performed in triplicate and each experiment was independently replicated three times.   After the 
addition of all components each assay incubated for 60 min at room temperature before filtration 




then determined by scintillation counting with a Wallac 1450 Microbeta counter (Perkin Elmer).  
Further methodological details have been published previously (Lamberts et al., 2013). 
Western blotting. Hippocampal homogenates containing 20 μg of protein were mixed with 
sample buffer (63 mM Tris, pH 6.8, with 2% sodium dodecyl sulfate (SDS), 10% glycerol, 
0.008% bromophenol blue, and 50 mM dithiothreitol) and 50 mM pH 7.4 Tris buffer to a total 
volume of 25 μl.  Samples were then separated by SDS-PAGE using polyacrylamide gels and 
transferred to a nitrocellulose membrane (Pierce).  Membranes were probed with primary 
antibodies against each Gα subtype (Gαo, Gαi1, Gαi2, Gαi3, Gβγ(1-6) and RGS19; Santa Cruz 
Biotechnology).  Each membrane was also stripped and re-probed with a primary antibody 
specific for α-Tubulin as a loading control (Sigma-Aldrich).  Horseradish peroxidase-conjugated 
anti-mouse and anti-rabbit secondary antibodies were used for chemiluminescent detection in 
combination with SuperSignal™ West Pico Chemiluminescent Substrate (ThermoFisher 
Scientific).  Signal intensity was determined using ImageJ software 
(http://rsbweb.nih.gov/ij/index.html). 
8-OH-DPAT induced hypothermia.  Two hours before experiment mice were moved from 
group housing to individual cages for testing.  Free access to food and water was maintained 
during this time.  Baseline temperatures were taken once every 10 min for 30 min before 
experimental treatment.  The final baseline recording was used as the reported baseline 
measurement.  Temperatures were determined using a Tcat 2df controller rectal thermometer 
(Physitemp Clifton, NJ) inserted to a 20 mm probe depth.  All animals in this study received both 
an i.p. and an intra-hippocampal injection, with the i.p. injection immediately following the third 
baseline measurement and intra-hippocampal infusion immediately following i.p. injection.  
Drug effects were determined 10, 20 and 30 min after injection for each animal. 
Statistical analysis.  GraphPad Prism 7.0 (GraphPad; LaJolla, CA) was used to analyze all 
reported data.  2-way analysis of variance (2-way ANOVA) followed by Tukey’s post-hoc test 
for multiple comparisons was used to analyze data involving two independent drug treatments as 
well as data involving a genetic variable and a drug treatment.  If statistics for a main effect, 
interaction or post-hoc comparison are not detailed in the results these effects did not reach 
significance.  Experiments involving only one independent variable were analyzed by student’s 




experiments Kd and Bmax were obtained using a one-site saturation binding curve with Hill 
slope set to 1 as described previously (Lamberts et al., 2013).   
 
Results 
Effects of intra-hippocampal WAY100635 in wild type and Gαi2 GS/GS mice 
Homozygous Gαi2 
GS/GS knock-in mice given saline bilaterally into the hippocampus exhibited 
less immobility in the TST than their wild type littermates (Figure 2.1), confirming that the intra-
hippocampal microinjection procedure does not disrupt the previously described antidepressant-
like phenotype in these mice.  Bilateral intra-hippocampal administration of WAY100635 (3 μg 
each side) fully reversed this baseline reduction in immobility back to levels seen in wild type 
littermates. WAY100635 similarly administered to wild type (WT) littermates had no effect 
(Figure 2.1).  Two-way ANOVA revealed significant main effects of genotype (F(1,22)=7.053, 
Fig. 2.1: Effects of the 5-HT1A antagonist WAY100635 on spontaneous antidepressant-
like behavior in homozygous RGSi Gαi2 expressing mice (GS/GS).  Antidepressant-like 
behavior in RGSi Gαi2 expressing mice in the tail suspension test is reversed by intra-
hippocampal WAY-100635 (3 μg/side).  Each column depicts the mean immobility score +/- 
SEM of 6-7 mice (2-way ANOVA followed by Tukey’s post-hoc test; significant main effects 
of genotype, treatment, and interaction; ** indicates a difference from saline treated wild type 




p=0.0144), treatment (F(1,22)=9.452, p=0.0055), and genotype x treatment interaction 
(F(1,22)=7.338, p=0.0128). 
 
Effects of intra-hippocampal 8-OH-DPAT on tail suspension test immobility and 
hypothermia in wild type mice 
The complete reversal of the Gαi2 
GS/GS behavioral phenotype by intra-hippocampal WAY100635 
suggests the hippocampus as the site of the increased 5-HT1AR signaling and thus of the 
antidepressant-like phenotype.  Therefore, we sought to test if we could mimic this behavioral 
phenotype by administering the 5-HT1AR agonist 8-OH-DPAT directly into the hippocampus of 
wild type Gαi2 
+/+ mice.  Intra-hippocampal 8-OH-DPAT (3 μg) bilaterally into the hippocampus 
Fig. 2.2: Effects of intrahippocampal 8-OH-DPAT administration in wild type mice.  (A) Intra-HPC 8-OH-DPAT 
produces a WAY-100635 reversible antidepressant-like effect in the tail suspension test in wild type mice. All animals 
received both an intra-hippocampal infusion and s.c. injection.  Each column depicts the mean immobility score +/- 
SEM of 6 mice (2-way ANOVA followed by Tukey’s post-hoc test; significant main effects of WAY and 8-OH-DPAT 
treatments; *** indicates a difference from saline/saline treated condition (p<.001); ## indicates a difference from mice 
receiving intra-HPC 8-OH-DPAT and s.c. saline (p<.01)).  (B) Intrahippocampal 8-OH-DPAT does not produce a 
hypothermic effect at doses capable of producing antidepressant-like effects.  All animals received both an intra-
hippocampal infusion and i.p. injection.  Each line represents the mean temperature +/- SEM recorded from 6-7 mice at 
multiple timepoints (2-way ANOVA followed by Tukey’s post-hoc test; significant main effects of treatment, time and 
interaction; **, *** and **** indicate a difference between 1 mg/kg 8-OH- DPAT i.p. and vehicle treated animals at 
that timepoint (p<.01, p<.001 and p<.0001 respectively); #### indicates a difference between 10 mg/kg DPAT i.p. and 
vehicle treated animals at that timepoint (p<.0001)).   Animals receiving 3 μg/side DPAT intra-HPC were not 






+/+ mice reduced immobility.  This action of 8-OH-DPAT was significantly attenuated by 
systemic (s.c) administration of 0.1 mg/kg WAY100635 (Figure 2.2A).  This dose of 
WAY100635 did not affect the behavior of animals given an intra-hippocampal saline infusion 
(Figure 2.2A).  Two-way ANOVA revealed significant main effects of 8-OH-DPAT treatment 
(F(1,20)=10.57, p=0.0040), and WAY100635 treatment (F(1,20)=43.55, p<0.0001).  
Activation of 5-HT1ARs in the raphe nuclei modulates body temperature (Hillegaart 1991).  
Doses of 8-OH-DPAT which produce an antidepressant-like effect when administered 
peripherally (1 mg/kg and 10 mg/kg, i.p., see Figure 2.5B and Talbot et al., 2010) produced a 
lasting hypothermic effect in Gαi2 
+/+ animals (Figure 2.2B).  In contrast doses of 8-OH-DPAT 
which produce an antidepressant-like effect in the TST when administered into the hippocampus 
(3 μg/side) did not affect body temperature (Figure 2.2B).  Two-way ANOVA revealed 
significant main effects of treatment (F(3,84)=39.86, p<0.0001), time (F3,84)=20.24, p<0.0001), and 
treatment x time interaction (F(9,84)=5.011, p<0.0001). 
Recording of hippocampal slices from wild type and RGSi Gαi2 knock-in mice in the 
presence of 8-OH-DPAT 
Both 5-HT1AR and Gαi2 (see Figure 2.5B) are expressed in mouse hippocampus, in 
agreement with published results (Laporte et al., 1994; Allen Brain Atlas experiment numbers 
79556616 and 2263).  Based on the above results and our previous findings (Talbot et al., 2010) 
we predicted that the decreased immobility in the Gαi2 
GS/GS mice is due to increased activation 
of hippocampal 5-HT1ARs coupled to Gαi2. Activation of 5-HT1A receptors reduces membrane 
excitability by altering intrinsic membrane properties.  For example, 5-HT1AR activation alters 
potassium currents and hyperpolarization-activated currents to regulate cell excitability (Ko et 
al., 2016; Andrade et al., 1987; Colino et al., 1987; Oleskevich et al., 1995). Therefore, to test 
for altered 5-HT1AR activity, we compared the effect of 5 μM 8-OH-DPAT between 
heterozygous Gαi2 
GS/+ and Gαi2 
+/+ littermates on excitability of CA1 hippocampal neurons. 
Heterozygous mice were used because the homozygous animals already show a maximal 
antidepressant-like effect in the tail suspension test (Talbot et al., 2010) and we have previously 
shown that this 5-HT1AR agonist has increased potency in the heterozygotes (Talbot et al., 
2010). We recorded the responses of CA1 hippocampal neurons to current injection from -200 






GS/+ littermates (Gαi2 
GS/+ n=7 cells from 3 mice; Gαi2 
+/+ n=9 cells from 5 mice for all 
measures). Application of 8-OH-DPAT did not affect neuronal excitability in Gαi2 
+/+ mice 
(Figure 2.3A: 2-way RM ANOVA, treatment x current injection interaction: F(14,112)=0.8026, 
p=0.6647); example traces shown in Figure 2.3C. In contrast, the same 8-OH-DPAT treatment 
significantly decreased excitability in the Gαi2 
GS/+ mice (Fig 2.3B: 2-way RM ANOVA, 
treatment x current injection interaction: F(14,84)=2.632, p=0.0033); example traces shown in Fig 
2.3D.  Thus, consistent with behavioral data above, 5 μM 8-OH-DPAT decreased membrane 
excitability in hippocampal CA1 neurons from Gαi2 
GS/+ mice, but not in neurons from Gαi2 
+/+ 
littermates.  Higher concentrations of 8-OH-DPAT produce similar effects in wild type animals 
(Czyrak et al., 2002) suggesting that 5-HT1A agonist potency is increased in Gαi2 
GS/+ mice. 
In addition, bath application of 8-OH-DPAT produced a significant decrease in resting 
membrane potential in cells from the Gαi2 
GS/+ mice (Figure 2.3F; t6=6.9; p<0.001), but not their 
Gαi2 
+/+ littermates (Figure 2.3E; t8=1.02, p=0.34) and the minimum amount of current needed to 
reach the firing threshold (i.e. the rheobase) was significantly increased by 8-OH-DPAT in cells 
from the Gαi2 
GS/+ mice (Figure 2.3E; t6=4.25, p<0.01), but not in cells from Gαi2 
+/+ mice (Figure 
2.3F; t8=1.31, p=0.23).  Overall, the results demonstrate that 5 μM 8-OH-DPAT application 
caused a decrease in membrane excitability in hippocampal CA1 neurons only from Gαi2 
GS/+ 
mice, but this concentration was ineffective in neurons from Gαi2 
+/+ littermates, showing 





Fig. 2.3: Recording from hippocampal slices in the presence of 8-OH-DPAT from wild type and RGSi Gαi2 
knock-in mice. (A) Application of 8-OH-DPAT did not affect neuronal excitability in wild type mice (Gαi2 +/+; 2-
way RM ANOVA, treatment x current injection interaction: F(14,112)=0.8026, p=0.6647). (B) Application of 8-OH-
DPAT decreased neuronal excitability in heterozygous RGSi Gαi2 mice (Gαi2 GS/+; 2-way RM ANOVA, treatment 
x current injection interaction: F(14,84)=2.632, p=0.0033). (C) Example traces of data quantified in 2.3A. (D) 
Example traces of data quantified in 2.3B. (E) Bath application of 8-OH-DPAT produced no significant changes in 
measured currents in cells from wild time mice (Gαi2 +/+ mice; t-test performed between baseline and 5 μM 8-OH-
DPAT measurements, ** = p<.01). (F) Bath application of 8-OH-DPAT produced a significant decrease in resting 
membrane potential (RMP) and increased rheobase in cells from the heterozygous RGSi Gαi2 mice (Gαi2 GS/+), but 
did not affect input resistance (IR) (t-test performed between baseline and 5 μM 8-OH-DPAT measurements, ** = 
p<.01, *** = p<.001; n=9 cells recorded for each measure, data expressed as mean +/- SEM; 0 indicates terminal 












Effects of an RGS inhibitor (CCG-203769) on tail suspension test immobility in male and 
female wild type mice 
We have previously suggested that RGS19 acts as a negative modulator of 5-HT1AR signaling 
in mouse hippocampal neurons in vitro (Wang et al., 2014).  To examine if this is a critical 
component of the 5-HT1AR signaling pathway in the hippocampus in vivo we used the 
RGS4/RGS19 inhibitor CCG-203769 (Blazer et al., 2015).  A single intra-hippocampal 
administration of CCG-203769 (3 μg/side) produced a non-significant trend towards decreased 
immobility in the tail suspension test (data not shown).  However, CCG-203769 is an irreversible 
inhibitor of RGS4 and RGS19.  Therefore, to further inhibit RGS4/19 activity we gave three 
infusions each separated by 24h.  After this treatment, female wild type mice showed a 
significant reduction in immobility compared to vehicle treated controls, while there was no 
significant effect in male animals (Figure 2.4A).  Two-way ANOVA revealed significant main 
effects of sex (F(1,21)=15.68, p=0.0007), treatment (F(1,21)=4.354, p=0.0493), and sex x treatment 
interaction (F(1,21)=6.361, p=0.0198).  In contrast, there was no significant difference in the 
potency of 8-OH-DPAT to produce antidepressant-like effects between male and female wild 
type mice (Figure 2.4B).  Two-way ANOVA revealed a significant main effect of treatment 
(F(4,51)=9.058, p<0.0001), but not sex (F(1,51)=0.1785, p=0.6745) or sex x treatment interaction 
(F(4,51)=1.706, p=0.1630).  Hippocampal homogenates from male and female wild type mice did 
not differ in RGS19 protein expression as determined by western blot (Figure 2.4C).  
Hippocampal G-protein expression and [3H]8-OH-DPAT binding in wild type and RGSi 
Gαi2 knock-in mice 
In order to determine whether the electrophysiological and behavioral changes observed in the 
RGSi Gαi2 mice could be explained by compensatory changes in 5-HT1AR expression, we 
characterized 5-HT1AR ligand binding in the mouse hippocampus.  Saturation binding with 
[3H]8-OH-DPAT was performed in hippocampal membrane homogenates from wild type and 
heterozygous (+/GS) RGSi Gαi2 mice (Figure 2.5A).  Neither the maximal receptor expression 
(Bmax) nor the affinity (Kd) of [3H]8-OH-DPAT binding were significantly different between 









Fig. 2.4: Intra-hippocampal CCG-203769 administration produces antidepressant-like effects in female 
mice.  (A) Administered once daily for three days intra-hippocampal CCG-203769 (CCG; 3 μg/side) produces an 
antidepressant-like effect in female but not male wild type mice.  Each column depicts the mean immobility score 
+/- SEM of 6-7 mice (2-way ANOVA followed by Tukey’s post-hoc test; significant main effects of sex, treatment 
and interaction; * indicates a difference from vehicle treated female mice (p<.05); ### indicates a difference from 
CCG-203769 treated male mice (p<.001)).  (B) This sex difference cannot be explained by differential sensitivity 
to the antidepressant-like effects of 5-HT1A activation.  Each point in (B) represents the mean immobility score +/- 
SEM of 6-7 mice (2-way ANOVA followed by Tukey’s post-hoc test; significant main effect of treatment; * 
indicates a difference between 1 mg/kg 8-OH-DPAT and vehicle treated male animals (p<.05); # indicates a 
difference between 1 mg/kg DPAT and vehicle treated female animals (p<.05).  (C) Hippocampal RGS19 
expression. RGS19 signal intensity was normalized to α-Tubulin expression for each sample, and ratio of G-
protein/α-Tubulin expression was averaged across three independent experiments +/- SEM (RGS19 signal intensity 
was compared between male and female animals with unpaired t-test, no significant difference).  Representative 
blot shows RGS19 bands detected at ~25 kDa for hippocampal homogenates from female mice (lanes 1-3) and 















Fig. 2.5: Hippocampal [3H]8-OH-DPAT binding and G-protein expression is unaltered in heterozygous 
RGSi Gαi2 knock-in mice.  (A) Specific binding of 8-OH-DPAT:  Each point represents the mean specific 
binding +/- SEM from three independent experiments (best fit lines for Kd and Bmax calculation were 
determined using a one-site saturation binding fit with Hill slopes set to 1 and fitted to mean results averaged 
across experiments; Bmax and Kd compared between WT and +/GS using unpaired t-test, no significant 
differences).  (B) G-protein signal intensity was normalized to α-Tubulin expression for each sample, and 
mean G-protein/α-Tubulin expression +/- SEM was compared for three animals at each G-protein subunit 
(expression of each protein target for +/GS and GS/GS animals compared to WT expression using unpaired t-
test, no significant differences).  (C) In each blot, the first three lanes show hippocampal samples from wild 
type (WT) mice, lanes 4-6 show hippocampal samples from heterozygous RGSi Gαi2 mice (+/GS), and lanes 




















Hippocampal homogenates from wild type and RGSi Gαi2 knock-in mice were assayed by 
western blotting.  Primary antibodies against Gαo, Gαi1, Gαi2, Gαi3 and Gβγ(1-6) were used to 
screen for expression 
differences of these proteins 
in the hippocampus (Figure 
2.5B).  There were no 
significant differences in 
protein expression between 
RGSi Gαi2 mice and wild 
type controls. 
  
Fig. 2.6: Spontaneous antidepressant-like behavior in mice expressing RGSi Gαo is not 
reversed by the 5HT1A antagonist WAY100635.  Antidepressant-like behavior in heterozygous 
RGSi Gαo (+/GS) expressing mice in the tail suspension test is not reversed by s.c. WAY-100635.  
Each column depicts the mean immobility score +/- SEM of 4-13 mice (2-way ANOVA followed 
by Tukey’s post-hoc test; significant main effect of genotype; ** and * indicate a difference from 
saline treated wild type condition, p<.01 and p<.05 respectively).  
 
Table 2.1: Bmax and Kd of hippocampal [3H]8-OH-DPAT 
binding.  Bmax and Kd were compared between WT and 
heterozygous RGSi Gαi2 mice (+/GS) using unpaired t-test, no 





Effects of peripheral WAY100635 on tail suspension test immobility in wild type and 
heterozygous RGSi Gαo knock-in mice 
Gαi2 appears to play a critical role in regulating antidepressant-like behavior via the 5-HT1AR as 
RGSi Gαi2 knock-in mice have an antidepressant-like phenotype, while Gαi2 knockout mice 
exhibit pro-depressant behaviors (Talbot et al., 2010).  However, 5-HT1ARs also couple to Gαo 
especially in the frontal cortex and hippocampus (La Cour et al., 2006). To examine whether loss 
of RGS control of Gαo similarly affects behavior, we studied mice expressing RGSi Gαo proteins 
(Fu et al., 2006).  The homozygous knock-in mice are not viable so we used heterozygotes. 
These mice also showed a reduction in immobility compared to wild type littermates in the TST 
(Figure 2.6).  However, unlike the RGS-Gαi2 mice systemic (s.c.) injection of 0.1 mg/kg 
WAY100635 did not affect immobility time (Figure 2.6).  Two-way ANOVA revealed a 
significant main effect of genotype (F(1,30)=16.2, p=0.0004), but not treatment (F(1,30)=0.0191, 
p=0.9138) or genotype x treatment interaction (F(1,30)=0.08618, p=0.7711). 
 
Discussion 
The current results show that the antidepressant-like behavioral phenotype observed on the tail 
suspension test in mice expressing an RGSi knock-in variant of Gαi2 (Gαi2 
GS/GS) was fully 
reversed by administration of the 5-HT1AR antagonist WAY100635 locally to the hippocampus.  
Moreover, this behavioral phenotype was mimicked by hippocampal administration of the 5-
HT1AR agonist 8-OH-DPAT to mice expressing wild type Gαi2 (Gαi2 
+/+) that was in turn fully 
blocked by systemic WAY100635.  The behavioral phenotype of the RGSi Gαi2 mice was 
accompanied by increased activity of the agonist 8-OH-DPAT on hippocampal slices in the 
heterozygotes (Gαi2 
GS/+) such that a concentration of 8-OH-DPAT that was ineffective in slices 
from wild-type mice caused hyperpolarization in slices from the mutant mice. The lack of 
pretreatment changes in neuronal excitability suggest that the observed behavioral changes were 
not due to increased constitutive activity of hippocampal 5-HT1ARs, but were instead due to 
enhanced signaling of endogenous serotonin at this site.  There were no changes in hippocampal 
5-HT1ARs or their ability to activate G-proteins, nor any significant changes in hippocampal 
heterotrimeric G-protein subunit expression. These data suggest that promoting signaling 




like effects of 5-HT1AR agonism. We did not study the 5-HT1AR-rich frontal cortex but our 
finding that intra-hippocampal WAY100635 fully reverses the behavioral phenotype indicates 
that activation of hippocampal 5-HT1ARs appears to be necessary and sufficient to explain the 
antidepressant-like behavior in mice expressing RGSi Gαi2.   
While it remains difficult to develop drugs that will target a specific GPCR bound to a particular 
G-protein subunit, targeting RGS proteins may provide an additional level of selectivity.  RGS 
family members 2, 7, 8, 10, 14 and 19 are expressed in the hippocampus at high levels, while 4, 
5, 11 and 13 are expressed only moderately, and 3, 6, 9 and 16 are expressed at very low levels 
or are absent (Gold et al., 1997; Grafstein-Dunn et al., 2001).  RGS19 has especially high 
expression in the hippocampus compared to other brain regions (Grafstein-Dunn et al., 2001).  
Furthermore, RGS19 readily regulates 5-HT1AR function in isolated hippocampal neurons 
compared to other RGS proteins tested (Wang et al., 2014).  These properties make RGS19 an 
attractive target to selectively enhance hippocampal 5-HT1AR function for potential 
antidepressant effects while avoiding the drawbacks of activating all 5-HT1ARs expressed in the 
CNS. 
Due to the lack of highly selective RGS19 small molecule inhibitors we tested the effects of 
CCG-203769, an RGS4 and RGS19 dual inhibitor (Blazer et al., 2015).  CCG-203769 forms a 
disulfide bridge with these RGS proteins and permanently inactivates them (Turner et al., 2011).  
Repeated (3-day) administration of CCG-203769 bilaterally into the hippocampus was necessary 
to produce an anti-depressant-like effect, but surprisingly this was only seen in female mice.  
This sex difference was not explained by differences in hippocampal RGS19 protein expression 
as levels were similar between male and female mice.  In addition, there was no sex difference in 
the antidepressant-like effects of 8-OH-DPAT suggesting that a differential response to 5-
HT1AR activation is not the primary cause.  The disparity may be due to a lower potency of 
CCG-203769 in males compared to females rather than an all-or-none difference.  However, 
higher doses were not thoroughly tested in male mice because intra-hippocampal infusion of 
more than 3 μg/side CCG-203769 produced motor suppression and catatonia in both male and 
female mice (unpublished observation), although this motor suppressant effect was not 




Although RGS19 inhibition is a promising candidate mechanism for the antidepressant-like 
action in the Gαi2 
GS/GS mice and for CCG-203769’s antidepressant-like effects, inhibition of 
other RGS proteins may play a role.  Out of all the RGS proteins tested with CCG-203769 only 
RGS4 is inhibited more potently than RGS19 (Blazer et al., 2015).  On the other hand, 
overexpressed RGS4 does inhibit 5-HT1AR signaling in the raphe nuclei (Beyer et al., 2004), 
and genetic knockdown of RGS4 did not affect baseline antidepressant-like behaviors and 
decreased the potency of serotonergic antidepressants (Stratinaki et al., 2013) suggesting that 
RGS4 inhibition likely cannot explain the antidepressant-like effects seen in the Gαi2 
GS/GS mice 
or after CCG-203769 treatment.  In contract, RGS6 knockout (RGS6 -/-) mice do show a 5-
HT1AR-mediated baseline antidepressant-like phenotype (Stewart et al., 2014).  Whereas this 
behavioral response is consistent with antidepressant-like effects seen in the Gαi2 
GS/GS mice 
there is no evidence that CCG-203769 interacts with RGS6.  RGS6 is a member of the R7 family 
of RGS proteins that includes RGS6, 7, 9 and 11 (Hollinger and Helper, 2002).  CCG-203769 
has over 1000-fold selectivity for RGS19 compared to other R7 RGS family members (Blazer et 
al., 2015) and RGS6 lacks an available cysteine residue within the RGS box region to form a 
covalent interaction with CCG-203769.  In addition, the increased phospho-GSK3β levels seen 
in the Gαi2 
GS/GS mice (Talbot et al., 2010) are not seen in the RGS6-/- mice which instead show 
an increase in phospho-CREB (Stewart et al., 2014).  Thus, the mechanisms underlying the 5-
HT1AR-mediated phenotype in the RGS6-/- and Gαi2 GS/GS mice appear to be different.  
Nonetheless, the above discussion suggests that the complex of 5-HT1AR/Gαi2 with a specific 
RGS protein, possibly RGS19, might provide a suitable target for antidepressant drug therapy.  
Furthermore, this could offer an explanation for the selectivity of compounds developed by 
Newman-Tancredi et al which show preference for frontal cortex 5-HT1A heteroreceptors 
compared to raphe nuclei 5-HT1A autoreceptors (e.g. F15599; Newman Tancredi et al., 2009) or 
selectivity for 5-HT1A autoreceptors compared to other 5-HT1ARs (e.g. F13640 and F13714; 
Buritova et al., 2009).  The heteroreceptor selective F15599 also stimulates 5-HT1ARs coupled 
to Gαi more potently and efficaciously than 5-HT1ARs coupled to Gαo, while serotonin shows 
no G-protein preference (Newman Tancredi et al., 2009), supporting the notion that a small 




Surprisingly we found that heterozygous RGSi Gαo knock-in mice also have an antidepressant-
like phenotype. However, this behavioral phenotype was not reversed by the 5-HT1AR 
antagonist WAY100635, suggesting that the antidepressant-like behaviors displayed by the RGSi 
Gαi2 and RGSi Gαo mice are driven by distinct mechanisms.  Studies in E. coli suggest that the 
5-HT1AR couples more efficiently to Gαi2 than Gαo proteins (Bertin et al., 1992), so the lack of 
a 5-HT1AR dependent phenotype in the RGSi Gαo mice is not surprising.  Although 5-HT1AR 
do couple to other Gα proteins the close association between 5-HT1AR and Gαi2 is supported by 
a 5-HT1AR dependent antidepressant-like phenotype in the Gαi2 
GS/GS mice and a prodepressant 
phenotype in Gαi2 
-/- mice (Talbot et al., 2010).  
When both the therapeutic and detrimental effects of a drug are mediated by the same molecular 
target, developing new therapies is particularly challenging.  The 5-HT1A receptor has long been 
recognized as one such target, where activation of autoreceptors on serotonergic cells is 
generally considered detrimental while activating heteroreceptors expressed on cells downstream 
of the serotonin neurons produces beneficial effects (Artigas 1993; Blier and Abbott 2001).  A 
considerable amount of effort has thus been spent on identifying strategies to block the 5-HT1A 
autoreceptors without affecting heteroreceptor activity, or conversely activating heteroreceptors 
without stimulating autoreceptor activity (Blier et al., 1993; Romero et al., 1996; Rabiner et al., 
2000; Newman Tancredi et al., 2009).  The RGSi Gαi2 mutation appear to accomplish this as 
evidenced by a promotion of 5-HT1AR dependent antidepressant-like behaviors, but not 
hypothermic effects.  A therapeutic that can selectively enhance signaling through 5-HT1A/Gαi2 
complexes, or alternatively selectively inhibit RGS proteins acting at Gαi2, may dissociate the 
therapeutic and detrimental effects of 5-HT1A agonism with potential benefits for the 
neuropsychiatric treatment of depression.   
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RGS Regulation of Opioid Receptor Signaling and Antinociception 
 
Uncontrolled pain is a significant problem with as many as 20% of all adults experiencing 
chronic pain (Brattberg et al., 1989), and at least 10% of Americans experiencing severe pain in 
2015 (https://nccih.nih.gov/news/press/08112015).  Opioids have been used therapeutically to 
control pain for over 200 years (Weiser et al., 1956) and to this day remain as the most 
commonly used analgesic medications (Okie 2010).  Although non-opioid analgesics are 
available and effective for certain types of pain (e.g. COX-2 inhibitors for arthritic/inflammatory 
pain (Lee et al., 2005) or pregabalin for neuropathic pain (Verma et al., 2014), for many patients 
opioid analgesics remain the best available option.  This fact, along with an increased focus on 
controlling pain among physicians, has led to opioid prescriptions increasing by a factor of 10 
since just 1990 (Okie 2010).  The huge amount of opioid prescriptions has led to a dramatic 
increase in unintentional overdose deaths, with over a fourfold increase in the number of deaths 
since the early 1970’s (Okie 2010).  These drugs also have significant abuse liability, and a 
history of substance abuse disorders dramatically increases the risk of accidental overdose death 
for those prescribed opioid analgesics (Bohnert et al., 2011).   
Four types of opioid receptors have been identified: the mu opioid receptor (MOPR), delta 
opioid receptor (DOPR), kappa opioid receptor (KOPR) and nociceptin receptor (NOPR) 
(Goldstein and Naidu 1989; Bunzow et al., 1994).  While each of these receptors has the ability 
to regulate the perception of pain, all currently available opioid medications exert their analgesic 
effects by binding to and activating MOPR (Gunther et al., 2017).  Nonetheless, ligands acting at 
the other opioid receptors have been proposed as putative analgesic medications with improved 
side effect profiles compared to the current generation of opioid analgesics (Gunther et al., 




suggested, including the use of allosteric modulators of MOPR (Livingston and Traynor 2017) 
and biased agonists that can selectively stimulate analgesic pathways (Raehal et al., 2011; Siuda 
et al., 2017).  However much remains unknown about how these medications propagate their 
signal within the cell, including how various intracellular regulatory proteins affect this process.  
One such class of proteins known to affect opioid receptor signaling and resultant analgesia are 
the regulators of G-protein signaling (RGS) proteins.  These proteins are a 20+ member family of 
intracellular regulatory proteins characterized by an ‘RGS box’ domain (see Table 0.1; Hollinger 
and Hepler 2002).  This domain makes direct contact with activated GTP-bound Gα proteins and 
facilitates their inactivation through an intrinsic GTPase activating (GAP) activity (see Figure 
0.2; Tesmer et al., 1997; Lan et al., 2000).  This terminates G-protein signaling and allows the 
receptor to reassociate with the heterotrimeric G-protein complex. This inhibitory effect on G-
proteins allows RGS proteins to modulate the downstream effects of many GPCRs that are 
targeted by common pharmaceuticals including dopamine receptors (Wani et al., 2012), 
serotonin receptors (Ghavami et al., 2004) and opioid receptors (Clark et al., 2003) among many 
others.   
RGS proteins are extensively expressed throughout the central nervous system (CNS) and 
broadly overlap with opioid receptor expression (Gold et al., 1997; Peckys and Landwehrmeyer 
1999; Grafstein-Dunn et al., 2001; Traynor and Neubig 2005).  They display selectivity for 
certain G-protein subtypes over others (Posner et al., 1999; Lan et al., 2000) as well as 
selectivity for certain receptors (Xu et al., 1999; Wang et al., 2009).  Their selectivity and 
expression pattern make RGS proteins attractive drug targets, and small molecule RGS inhibitors 
have now been identified (Roof et al., 2006; Roman et al., 2007).  Furthermore, RGS proteins 
regulate the effects of drugs acting at the opioid receptors in ways that are not yet entirely clear.  
Therefore, this chapter will focus on the interaction between opioid receptors and RGS proteins 
and the implications for analgesic treatment.  Table 3.1 provides a general summary of findings 
discussed below relating to RGS protein regulation of MOPR, DOPR, KOPR and NOPR. 
R4 RGS family regulation of MOPR signaling and antinociception 
The regulation of MOPR signaling by RGS4 is one of the most well characterized RGS/receptor 
pairings.  RGS4 has widespread distribution throughout the CNS where it can regulate the 




proposed to interact directly with MOPR via an interaction between the fourth-intracellular loop 
of MOPR (residues 329–355) and RGS4’s N-terminal domain (Leontiadis et al., 2009).  
Removal of the RGS4 N-terminal domain not only reduces receptor/RGS4 interactions but also 
eliminates receptor selectivity seen with the endogenous RGS4 protein (Zeng et al., 1998; 
Leontiadis et al., 2009).  In a resting state RGS4 binds weakly to Gαi/o proteins, but this 
interaction is greatly enhanced by MOPR activation (Leontiadis et al., 2009).  When 
overexpressed in HEK293 cells RGS4 has a diffuse localization throughout the cytosol, nucleus 
and plasma membrane, however following application of the MOPR agonist DAMGO 
expression shifts to the plasma membrane such that RGS4 is colocalized with MOPR (Leontiadis 
et al., 2009).  In contrast, in SH-SY5Y cells that endogenously express RGS4 and MOPR, 
Table 3.1: General overview of findings described in this chapter showing RGS protein regulation 
of MOPR, DOPR, KOPR and NOPR-mediated effects.  Blank entries indicate insufficient data to 




knockdown of RGS4 did not affect responses to the MOPR agonist morphine (Wang et al., 
2009) suggesting that the ability of RGS4 to regulate MOPR may be cell type dependent. 
Following partial sciatic nerve ligation rats become hyperalgesic and MOPR agonists decrease in 
potency (Garnier et al., 2003).  This coincides with an upregulation of RGS4 mRNA expression 
in the dorsal horn of the spinal cord, but no change in the mRNA of other RGS proteins tested 
(RGS6/7/8/9/11/12/14/17/19; Garnier et al., 2003).  The possibility that this compensatory 
change in RGS4 contributes to the loss of MOPR agonist potency is bolstered by the fact that 
overexpression of RGS4 reduces the ability of MOPR agonists to inhibit adenylyl cyclase in 
vitro, and that RGS4 and MOPR show significant expression overlap within the dorsal horn 
(Peckys and Langwehrmeyer 1999; Garnier et al., 2003).  In dorsal root ganglion primary 
sensory neurons however, RGS4 mRNA decreases following sciatic nerve injury (Costigan et 
al., 2003), suggesting a cell type dependent regulation of this transcript between the dorsal root 
ganglion and dorsal horn of the spinal cord.  
In support of changes dependent on duration of exposure, acute administration of morphine 
causes an upregulation of RGS4 mRNA levels in the dorsal central gray and nucleus accumbens, 
but reduces RGS4 mRNA in the reticulotegmental pontine nucleus and locus coeruleus (Bishop 
et al., 2002).  Both the dorsal central gray (Guimaraes and Prado 1994; Helmstetter and Tershner 
1994) and nucleus accumbens (Han et al., 2010) are known to contribute to the antinociceptive 
effects of opioids.  RGS4 upregulation in these regions would therefore be expected to attenuate 
the analgesic effects of opioids and may be involved in the development of opioid tolerance 
following repeated administration (Bishop et al., 2002).  Locus coeruleus RGS4 mRNA was not 
altered during chronic morphine exposure, but increased 2 to 3-fold following naltrexone 
precipitated withdrawal (Gold et al., 2003).  Interestingly RGS4 mRNA also increases in the 
locus coeruleus following naltrexone administration to opioid naïve animals, suggesting that 
endogenous opioids may tonically inhibit locus coeruleus RGS4 expression (Gold et al., 2003). 
In PC12 cells that endogenously express RGS4 the MOPR agonists morphine and DAMGO 
increase RGS4 mRNA expression transiently over the course of 8-12 hours before mRNA levels 
return to basal levels (Nakagawa et al., 2001).  This time course reflects the results observed in 
the locus coeruleus where acute morphine treatment increases RGS4 mRNA (Bishop et al., 




(Gold et al., 2003).  On the other hand, RGS4 protein levels increase during chronic morphine 
treatment (Gold et al., 2003), although it remains unclear whether these changes contribute to 
either the development of opioid tolerance or the withdrawal syndrome following chronic opioid 
exposure.   
Intracellular application of purified RGS4 to locus coeruleus neurons attenuated the 
electrophysiological response to acute morphine, confirming that increased levels of RGS4 in 
this brain region can counteract opioid effects (Gold et al., 2003).  Overexpression of RGS4 also 
attenuated the ability of MOPR agonists to inhibit adenylyl cyclase activity and stimulate MAPK 
in HEK293 cells (Leontiadis et al., 2009) and activate GIRK in Xenopus oocytes (Ippolito et al., 
2002).  On the other hand, the MOPR agonist DAMGO inhibited firing of locus coeruleus 
neurons to the same extent in wild type and RGS4 knockout mice (Han et al., 2010) and in SH-
SY5Y cells RGS4 knockdown had no effect on morphine stimulated MAPK or adenylyl cyclase 
activity (Wang et al., 2009).  One possible explanation for this discrepancy is that in knockdown 
models other RGS proteins are able to fully compensate for the loss of RGS4, while increasing 
RGS4 expression further inhibits opioid activity, although this hypothesis has not been 
confirmed.  However, even the results of RGS4 overexpression studies are not fully consistent, 
as RGS4 overexpression in xenopus oocytes has been reported alternatively to attenuate MOPR 
signaling (Ippolito et al., 2002) or have no effect (Potenza et al., 1999) although this may result 
from the use of different agonists (morphine and DAMGO respectively).  Indeed, RGS4 
regulation of MOPR agonist-induced antinociception is strongly agonist-dependent, as RGS4 
knockout mice are less sensitive to the antinociceptive effects of both fentanyl and methadone, 
while the antinociceptive effect of morphine is not affected (Han et al., 2010).  This lack of an 
RGS4 effect with morphine is not consistent across studies however, as mice administered 
antisense-DNA against RGS4 had a greater response to intracerebroventricular (i.c.v.) morphine 
compared to controls (Garzon et al., 2001), although different routes of administration between 
these two studies (i.c.v. vs. subcutaneous injection) may contribute to this discrepancy. 
The ability of RGS4 to regulate fentanyl antinociception appears to depend on nucleus 
accumbens RGS4 expression, as specific knockdown in this brain region also reduces fentanyl 
antinociception (Han et al., 2010).  While the upregulation of nucleus accumbens RGS4 mRNA 




morphine’s antinociceptive effects after repeated administration (Bishop et al., 2002), RGS4 
protein levels in the nucleus accumbens are not significantly elevated following repeated 
morphine exposure in mice (Narita et al., 2002).  However, in this study morphine was only 
administered once every 72 hr (Narita et al., 2002) whereas studies showing effects on brain 
RGS4 protein level administered morphine continuously over 5 days (Gold et al., 2003).  
Therefore, the possibility remains that opioid effects on brain RGS4 protein expression may 
require more frequent dosing. 
The injection of formalin into a mouse hind paw produces a biphasic hyperalgesic behavior with 
an early phase and a late phase that are differentially regulated by RGS4 (Yoon et al., 2015).  
RGS4 knockout mice spend less time licking (i.e. are less hyperalgesic) during the late phase of 
formalin hyperalgesia, but behave similar to wild type controls during the early phase (Yoon et 
al., 2015).  The antihyperalgesic effect of the MOPR agonist DAMGO was left-shifted over 10-
fold in RGS4 knockout animals compared to wild type, confirming the ability of RGS4 to limit 
antihyperalgesic effects of exogenous opioids (Yoon et al., 2015).  Similarly, intrathecal 
injection of the small molecule RGS4 inhibitor CCG50014 (Roman et al., 2007) to wild type 
mice produced a dose dependent reduction in licking during the late phase without affecting 
early phase behavior (Yoon et al., 2015).  This effect of CCG50014 was completely blocked by 
naloxone pretreatment, confirming the involvement of opioid receptors in this response (Yoon et 
al., 2015). Despite these antihyperalgesic effects of RGS4 inhibition, healthy RGS4 knockout 
mice do not display alterations in pain sensitivity when tested on the tail flick, hot plate or shock 
threshold tests, either at baseline or following morphine administration (Grillet et al., 2005).  
This suggests that RGS4 may regulate the antihyperalgesic effects of opioids rather selectively 
compared to their antinociceptive effects in healthy animals. 
Less is known about how R4 RGS family members other than RGS4 (e.g. 
RGS1/2/3/5/8/13/16/18; Hollinger and Helpler 2002) regulate MOPR signaling.  Locus 
coeruleus RGS2 showed a very similar change in expression to RGS4 following morphine 
exposure, with an increase in protein level during chronic morphine treatment and an increase in 
mRNA level following naltrexone precipitated withdrawal (Gold et al., 2003).  Out of the RGS 
proteins known to be expressed in the locus coeruleus (RGS2/3/4/5/7/8/11) only RGS2 and 




modulating MOPR signaling as GTP hydrolysis stimulated by DAMGO in C6 cells is inhibited 
by the addition of purified RGS8 (Clark et al., 2003; Talbot et al., 2010), so in the locus 
coeruleus RGS8 may not be expressed in the appropriate cell type or at sufficient levels to 
regulate MOPR signaling.  In a melanophore based assay overexpression of RGS2, but not 
RGS1, RGS3 or RGS4 potentiated morphine’s effects (Potenza et al., 1999), so despite similar 
regulation of RGS2 and RGS4 in the locus coeruleus, these proteins appear to regulate MOPR 
signaling differently in certain cell types.  
In agreement with the findings of Potenza et al (1999) knockdown of RGS2 and RGS3 had no 
effect on baseline antinociception but paradoxically inhibited the antinociceptive response to 
morphine and beta-endorphin on the tail flick test (Garzon et al., 2001).  In contrast RGS16 
knockdown increased the antinociceptive response to morphine without changing baseline 
behavior, a profile similar to the behavior of RGS4 knockdown animals (Garzon et al., 2001).  
The basis of these opposing effects of different R4 family members has not been adequately 
explored, although it has been suggested that distinct Gα interaction profiles between the 
different RGS proteins may be responsible (Garzon et al., 2000; Garzon et al., 2001). 
R7 RGS family regulation of MOPR signaling and antinociception 
The R7 family of RGS proteins, including RGS6, RGS7, RGS9-1, RGS9-2 and RGS11 
(Hollinger and Hepler 2002), have also been extensively studied in terms of their ability to 
regulate MOPR signaling.  Cells transfected with RGS9-2 (but not the retina specific variant 
RGS9-1) had an attenuated response to morphine in a melanophore based assay (Rahman et al., 
1999).  Although mice administered antisense-DNA against RGS7 or RGS9-2 i.c.v. had no 
baseline change in antinociception, knockdown of either protein resulted in greater responses to 
morphine, DAMGO and beta-endorphin on the tail flick test (Sanchez-Blazquez et al., 2003; 
Garzon et al., 2001).  Knockdown of RGS9-2 or RGS11 more effectively enhanced DAMGO 
induced antinociception than RGS6 or RGS7 knockdown (Garzon et al., 2003).  Together these 
data show selectivity within the R7 family for control of MOPR signaling, with RGS9-2 and 
RGS11 producing greater effects than RGS6 and RGS7, while the retinal specific variant RGS9-
1 is incapable of regulating MOPR signaling.  One mechanism of R7 modulation of MOPR 




(GIRK) signaling, as elimination of the R7 RGS binding protein (R7BP) disinhibits MOPR 
agonist stimulated GIRK activity (Zhou et al., 2012). 
In permeabilized C6 cells expressing MOPR and Gαi2, addition of the RGS box region of RGS7 
did not affect DAMGO-induced inhibition of cAMP accumulation (Talbot et al., 2010).  When 
Gαo was expressed instead of Gαi2, the addition of RGS7 box region effectively inhibited 
DAMGO’s effects (Talbot et al., 2010) suggesting that RGS7 selectively regulates the action of 
MOPR agonists depending on the G-protein expressed. This selectivity may be due to a lack of 
physical interaction between RGS7 and Gαi2 as increasing concentrations of Gαi2 effectively 
disrupted the RGS4/Gαo complex but not the RGS7/Gαo complex (Talbot et al., 2010), 
suggesting that the inability of RGS7 to regulate MOPR signaling in cells expressing Gαi2 is due 
to a failure of RGS7/Gαi2 complex formation. 
RGS9-2 knockout mice have both a baseline decrease in nociceptive responding and an 
increased antinociceptive response to morphine (Papachatzaki et al., 2011).  Similarly, the 
antinociceptive action of morphine is enhanced in animals with either partial or complete RGS9-
2 knockdown in the brain (Sanchez-Blazquez et al., 2003; Garzon et al., 2001; Zachariou et al., 
2003).  RGS9-2 knockout also reduces thermal hyperalgesia and mechanical allodynia in a 
spared nerve injury model (Terzi et al., 2014), although the receptor(s) involved in these 
behaviors were not explored.  In mice with endogenous RGS protein levels, nerve injury caused 
a transient reduction in spinal cord RGS9-2 (as well as reduced expression of the R12 family 
member RGS10), followed by upregulated RGS9-2 levels in the nucleus accumbens at later 
points, suggesting possible loci for RGS influence on neuropathic pain (Alqinyah et al., 2017; 
Terzi et al., 2014). 
RGS9-2 knockdown also delays tolerance and enhances antinociception following chronic 
morphine exposure (Zachariou et al., 2003).  When RGS9 was knocked down in HN9.10 cells 
stably expressing the MOPR, chronic morphine treatment produced less upregulation of adenylyl 
cyclase activity and no longer shifted the potency of DAMGO, consistent with the reduced 
tolerance observed in animal models (Xu et al., 2004; Zachariou et al., 2003).  Furthermore, 
morphine treatment enhances the interaction between RGS9-2, MOPR and beta-arrestin, and 
RGS9-2 overexpression delays morphine induced MOPR internalization (Psifogeorgou et al., 




acute morphine treatment (Ibi et al., 2011).  However, in mice lacking Nox1, the catalytic 
subunit of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, both the association 
of the RGS9-2/Gαi2 complex and the phosphorylation of RGS9-2 are attenuated (Ibi et al., 2011).  
This suggests a mechanistic linkage between RGS9-2 and NADPH oxidase, which has 
previously been associated with the development of morphine tolerance (Doyle et al., 2010).  
Despite the delayed development of tolerance after loss of RGS9-2, RGS9-2 knockdown animals 
also somewhat paradoxically displayed increased physical dependence and withdrawal from 
chronic morphine (Zacharioiu et al., 2003), suggesting that RGS9-2 regulates tolerance and 
dependence independently.   
In animals with endogenous RGS9-2 levels acute peripheral administration of morphine 
increased RGS9-2 expression throughout the CNS (including in the nucleus accumbens, 
periaqueductal gray, and spinal cord), while in contrast chronic morphine decreased RGS9-2 
levels (Zachariou et al., 2003).  Morphine administered i.c.v. produces similar effects, with 
increased RGS9-2 mRNA observed in the thalamus and elevated RGS7 in the thalamus, however 
RGS9-2 and RGS11 were reduced in the cortex (Lopez-Fando et al., 2005).  By day two of 
morphine treatment RGS7, RGS9-2, RGS11 and Gβ5 were all increased throughout the brain 
including the cortex, and these changes persisted over two weeks of continuous morphine 
delivery (Lopez-Fando et al., 2005).  It is unclear why chronic morphine both increased brain 
RGS9-2 mRNA (Lopez-Fando et al., 2005) and decreased RGS9-2 protein levels (Zachariou et 
al., 2003) in different studies, however the treatment schedule likely resulted in higher sustained 
morphine concentrations in the latter study. 
RGS9-2 is known to be differentially expressed throughout the pain pathway during different 
stages of development.  RGS9-2 expression is increased in the ventral and dorsal horn, caudate 
putamen, nucleus accumbens, olfactory tubercle and periaqueductal gray of 1-year old rats 
compared to 3-week old rats, while expression is decreased in the thalamus and locus coeruleus 
(Kim et al., 2005).  Almost all neuronal cells in the dorsal root ganglion (DRG) are positive for 
RGS9-2 however expression in this region was not affected by age (Kim et al., 2005).  
Gβ5 is unique among Gβ isoforms, with less than 50% homology to other family members and 
distinct effects on multiple effector pathways including MAPK and adenylyl cyclase (see 




the central G-protein gamma-like (GGL) domain expressed in R7 RGS proteins (Snow et al., 
1998; Levay et al., 1999), such that knockdown of Gβ5 may interfere with the activity of these 
RGS proteins.  Knockdown of Gβ5 in the brain by antisense DNA enhanced the potency of 
morphine and DAMGO to produce antinociception on the tail flick test (Sanchez-Blazquez et al., 
2003), which may reflect a reduced ability of R7 RGS proteins (normally in complex with Gβ5) 
to inhibit MOPR signaling.  In addition, morphine failed to produce acute tolerance following 
Gβ5 knockdown (Sanchez-Blazquez et al., 2003).  The fact that the loss of a G-protein subunit 
enhances the effects of MOPR agonists rather than inhibiting them is on its face paradoxical, 
however the finding that R7 RGS family members and Gβ5 appear to be co-regulated provides 
one potential explanation (Chen et al., 2000; Witherow et al., 2000), although R7 protein 
expression was not assessed following Gβ5 knockdown (Sanchez-Blazquez et al., 2003).   
R12 RGS family regulation of MOPR signaling and antinociception 
Knockdown of R12 RGS family members RGS12 and RGS14 increased the antinociceptive 
response to morphine on the tail flick test in the mouse without affecting baseline withdrawal 
latencies, similar to the effects of RGS16 knockdown (an R4 RGS family member; Garzon et al., 
2001).  RGS14 knockdown reduced the development of acute tolerance following morphine 
exposure, and these behavioral changes occurred alongside increased MOPR phosphorylation 
leading to internalization and recycling of the receptor (Rodriguez-Munoz et al., 2007a).  This 
suggests that in normal circumstances RGS14 limits agonist activity in a way that reduces both 
MOPR phosphorylation (e.g. by GRKs) and beta-arrestin-mediated endocytosis, leading to more 
robust receptor desensitization than in systems lacking RGS14 (Rodriguez-Munoz et al., 2007a).   
RZ RGS family regulation of MOPR signaling and antinociception 
SH-SY5Y cells endogenously express RGS19, as well as MOPR, DOPR and NOPR.  
Knockdown of RGS19 enhanced MOPR agonist induced MAPK stimulation and adenylyl 
cyclase inhibition (Wang and Traynor 2013) without affecting DOPR or NOPR agonist effects. 
RGS19 expression increased after overnight treatment with MOPR agonists, and inhibition of 
Gαi/o protein/receptor interaction with pertussis toxins prevented this upregulation (Wang and 
Traynor 2013).  The upregulation was also prevented by inhibition of either PKC or MEK (Wang 
and Traynor 2013), suggesting a pathway dependent on MOPR, Gαi/o proteins and PKC/MEK 




Knockdown of RGSZ-2 increased the antinociceptive response to morphine and DAMGO, and 
increased the rate at which tolerance developed to these antinociceptive effects (Garzon et al., 
2005).  These effects were specific for MOPR agonists as the actions of the DOPR agonists 
DPDPE and deltorphin II were not affected by RGSZ-2 knockdown (Garzon et al., 2005).  
Similarly, knockdown of two other RZ RGS family members, RGS19 (aka GAIP) and RGSZ1, 
enhanced the antinociceptive effects of morphine and DAMGO without affecting the response to 
DOPR agonists (Garzon et al., 2004).  In addition to these effects on antinociception, knockdown 
of either RGS19 or RGSZ1 increased the rate at which antinociceptive tolerance developed 
(Garzon et al., 2004).  Together these results suggest that all RZ RGS proteins are capable of 
both inhibiting MOPR agonists induced antinociception and reducing the development of 
tolerance following agonist exposure, likely through regulation of Gαz and Gαi2 (Garzon et al., 
2004; Garzon et al., 2005; Rodriguez-Munoz et al., 2007b). 
Treatment with morphine or DAMGO alters the proteins that Gαi2 interacts with (detected by co-
immunoprecipitation), decreasing associations between MOPR and Gαi2 but increasing 
associations between Gαi2 and RGSZ2 (Rodriguez-Munoz et al., 2007b).  This shift is transient, 
and the time course mimics the duration of antinociceptive tolerance following acute 
administration of morphine, such that Gαi2 interactions have returned to normal at time points 
when acute antinociceptive tolerance has waned (Rodriguez-Munoz et al., 2007b).  A similar 
process occurs with RGSZ2 and Gαz, with MOPR agonists increasing association between these 
proteins while decreasing Gαz/MOPR association (Garzon et al., 2005). 
RGSZ2 has also been identified as a linker between NMDA receptor signaling and MOPR which 
may contribute to the ability of the former receptor to attenuate antinociception produced by 
MOPR activation (Rodriguz-Munoz et al., 2015).  This regulation likely involves MOPR 
induced increases in nitric oxide causing enhanced NMDA receptor signaling in an RGSZ-2 
dependent manner (Garzon et al., 2011; Rodriguez-Munoz et al., 2015).   
RGS regulation of DOPR signaling and antinociception 
Although R7 (RGS6/7/9-1/9-2/11) and RZ (RGSZ1/RGS19) family members are capable of 
regulating MOPR signaling, knockdown of these proteins does not affect the response to DOPR 
agonists DPDPE or deltorphin II (Garzon et al., 2003; Garzon et al., 2004). Without agonist 




regions whereas DOPR is expressed near Gαi3 in non-clathrin-coated regions (Elenko et al., 
2003).  However following DOPR agonist treatment Gαi3 and RGS19 colocalize in clathrin 
coated regions and form a complex (Elenko et al., 2003).  This is reminiscent of the process 
described above where MOPR agonist treatment shifts Gαi2 and Gαz from a complex with 
MOPR to a complex with RGSZ-2 (Rodriguez-Munoz et al., 2007b).  When RGS19 interacts 
with Gαi3 in clathrin-coated regions following DOPR agonist treatment, RGS19 promotes the 
inactivation of Gαi3 at which point Gαi3 translocates back to a non-clathrin coated region and 
reassociates with DOPR (Elenko et al., 2003). This suggests that RGS19 can regulate DOPR 
signaling despite failing to modulate antinociceptive responses to DOPR agonists (Garzon et al., 
2004), or DOPR signaling in SH-SY5Y cells (Wang and Traynor 2013).  In fact, RGS19 more 
effectively attenuated the inhibitory effect of the endogenous DOPR agonist peptide leu-
enkephalin in NG-108 cell membranes than did RGS4 (Hepler et al., 1997), suggesting that 
DOPR regulation by RGS19 may also differ between cell types. 
In SH-SY5Y cells a 90% reduction of RGS4 significantly increased the ability of DOPR agonists 
to inhibit adenylyl cyclase and activate MAPK (Wang et al., 2009) while in HEK293 cells RGS4 
overexpression effectively reduced DOPR agonist stimulated signaling and increased the degree 
of DOPR internalization (Leontiadis et al., 2009).  This shows that despite being less effective 
than RGS19 at regulating DOPR signaling in NG-108 cell membranes (Hepler et al., 1997) 
RGS4 is still capable of significantly modulating the action of DOPR agonists. Indeed, RGS4 
knockout mice had enhanced antinociceptive and antihyperalgesic responses to the DOPR small 
molecule agonist SNC80 (Dripps et al., 2017).  SNC80 also more potently increases striatal 
MAPK phosphorylation in these animals, suggesting a potential downstream mechanism for the 
observed antinociceptive effects (Dripps et al., 2017).  Interestingly, the peripherally restricted 
DOPR antagonist N-methylnaltrexone blocked the antinociceptive effects of SNC80 on the 
acetic acid stretch assay but not its antihyperalgesic effects following nitroglycerin exposure 
(Dripps et al., 2017) in the RGS4 knockout mice, suggesting that loss of RGS4 enhances DOPR 
control of both peripheral and centrally-mediated pain perception.   
RGS regulation of KOPR and NOPR signaling 
In contrast to MOPR and DOPR, very little is known about how RGS proteins affect KOPR and 




600 base pairs, suggesting that these proteins may be co-regulated (Sierra et al., 2002).  In 
Xenopus oocytes RGS4 expression inhibits GIRK1 and GIRK2 signaling downstream of KOPR 
activation, and the presence of RGS4 appears to counteract cellular adaptations to sustained 
KOPR agonist treatment (Ulens et al., 2000).  In PC12 cells stably expressing KOPR, agonist 
application increased RGS4 mRNA expression in a KOPR antagonist reversible manner, a 
process that may contribute to desensitization of KOPR agonist responses (Nakagawa et al., 
2001). 
The genetic loci for NOPR and RGS19 neighbor each other, with RGS19 found only 83 base 
pairs from the 5’ end of the gene encoding NOPR (Ito et al., 2000; Xie et al., 2003).  This 83 
base pair region functions as a bidirectional promoter for both genes (Ito et al., 2000).  Despite 
this close co-regulation RGS19 and NOPR expression show distinct differences depending on 
cell type, as RGS19 is found in both undifferentiated and differentiated NT2 cells, while NOPR 
is expressed only after differentiation (Ito et al., 2000).  
 
Use of RGS Insensitive G-Protein Variants to Study Opioid Signaling 
A novel gain-of-function mutation originally identified in yeast Gα protein was found to mimic 
the effects of RGS knockdown (DiBello et al., 1998).  This mutation rendered Gα subunits 
totally insensitive to the negative regulatory effects of RGS proteins without otherwise affecting 
G-protein signaling (Lan et al., 1998; Fu et al., 2004), and produces similar effects in all Gαi/o 
proteins as well as Gαq (Kaur et al., 2011).  As these mutant RGS insensitive (RGSi) mutations 
eliminate the effects of all RGS proteins acting at a single Gα subunit there has been 
considerable interest in using these tools to probe opioid receptor signaling, both in vitro and in 
knock-in mouse models.   
MOPR agonists such as morphine and DAMGO increase intracellular calcium, increase MAPK 
phosphorylation, and inhibit adenylyl cyclase downstream of Gαo in C6 cells expressing MOPR 
(Clark et al., 2003).  When C6 cells expressing an RGSi variant of Gαo are used only the MAPK 
and adenylyl cyclase response are enhanced with no change in agonist stimulated calcium levels 
(Clark et al., 2003) suggesting that endogenous RGS proteins in these cells limit MOPR/Gαo 




Morphine’s potency is also enhanced in melanophores expressing MOPR and RGSi Gαi1 
compared to cells expressing wild type Gαi1 (Potenza et al., 1999) and in C6 cells expressing 
RGSi Gαi2 or Gαi3 (Clark et al., 2008). Together these data show that loss of RGS control at any 
of the four known Gαi/o proteins (Gαi1, Gαi2, Gαi3 and Gαo) can enhance the acute effects of 
MOPR agonists in vitro (Potenza et al., 1999; Clark et al., 2003; Clark et al., 2008; Talbot et al., 
2010).  
Morphine’s potency and maximal effect are enhanced to a greater degree than DAMGO’s in both 
C6 and SH-SY5Y cells expressing RGSi Gαo (Clark et al., 2003; Wang et al., 2009). In addition, 
the efficacy and potency of the MOPR weak partial agonist nalbuphine (Dykstra et al., 1997) 
was greatly enhanced in cells expressing RGSi Gαi2 or RGSi Gαi3, while the higher efficacy 
agonist DAMGO only increased in potency slightly (Clark et al., 2008).  These findings show a 
consistent pattern where loss of RGS 
control affects partial agonists to a greater 
degree than higher efficacy agonists (Clark 
et al., 2003; Clark et al., 2008; Wang et al., 
2009).   
In C6 cells with endogenous G-protein 
expression the withdrawal of MOPR 
agonists after sustained treatment produces 
the expected supersensitization of adenylyl 
cyclase, and this supersensitization is 
dependent on intact Gαo expression (Clark 
et al., 2004).  In cells expressing RGSi Gαo 
the magnitude of supersensitization was 
further enhanced, suggesting that 
endogenous RGS proteins acting at Gαo 
normally limit this supersensitizing 
response (Clark et al., 2004).   
Mice expressing RGSi Gαo (Goldenstein et 
al., 2009) displayed diminished 
Fig. 3.1: (A) Heterozygous RGSi Gαo knock-in mice 
(Gαo +/GS) display a naltrexone reversible baseline 
antinociceptive phenotype on the hot plate test. (B) In 
heterozygous RGSi Gαo knock-in mice (Gαo +/GS) 
morphine has increased antinociceptive potency on the 
hot plate test. 




nociceptive responses on both the hot plate and tail withdrawal tests, a behavioral phenotype that 
is completely reversible by naltrexone pretreatment (see Figure 3.1A; Lamberts et al., 2013).  
While the potency of the MOPR agonist morphine is enhanced on the hot plate (see Figure 
3.1B), its potency is paradoxically decreased in the tail withdrawal test (Lamberts et al., 2013) 
suggesting that the loss of RGS control may affect spinal antinociception (e.g. tail withdrawal 
test; Irwin et al., 1951) differently than supraspinal antinociception (e.g. hot plate test; 
Heinricher and Morgan 1998).  In periaqueductal gray slices GABA administration evokes 
inhibitory post-synaptic currents, and MOPR agonists inhibit these to a greater degree in mice 
expressing the RGSi Gαo protein (Lamberts et al., 2013).  This effect of MOPR agonists has 
been suggested to underlie the antinociceptive effects of these drugs (Moreau and Fields 1986; 
Reichling et al., 1988) suggesting that this signaling change may contribute to the observed 
behavioral changes.  Interestingly these mice also display increased itching behavior dependent 
both on the expression of KOPR and R7 binding protein (Pandey et al., 2017) suggesting that 
this mutation may affect behaviors downstream of the other opioid receptors as well.  
  
Conclusion 
While an extensive amount of research has been conducted on the interaction between MOPR 
and certain RGS proteins (e.g. RGS4) for other RGS/opioid receptor pairings, there is still very 
little information.  The effects of RGS proteins on NOPR and KOPR signaling in particular 
remains understudied, and the investigation of how RGS proteins affect DOPR signaling is just 
beginning to accelerate.  As more small-molecule RGS inhibitors are discovered the rate of 
progress in this area will likely continue to increase, and the use of RGSi G-protein variants 
provides an exciting alternative to traditional knockout models.   
Together the results summarized above suggest that RGS proteins are attractive targets that may 
allow more precise control of opioid analgesic effects, and RGS inhibiting molecules may even 
have stand-alone analgesic efficacy.  Despite the considerable challenge of studying a 20+ 
member protein family with occasionally redundant function, these possibilities warrant further 




The next chapter investigates how RGS proteins regulate the interaction between MOPR and 
NOPR using the RGSi Gαo knock-in mouse model.  This will add to the sparse available 
literature on interactions between NOPR and RGS proteins and will extend previous work which 
identified a complex opioid-receptor-dependent behavioral phenotype relating to pain perception 
in mice with genetic alterations in Gαo (Lamberts et al., 2011; Lamberts et al., 2013). 
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Loss of RGS Control at Gαo Produces a Nociception/Orphanin FQ Receptor Dependent 




Regulator of G-protein signaling (RGS) proteins bind to the active GTP-bound Gα subunit of 
heterotrimeric G-proteins to accelerate hydrolysis of GTP and limit signaling downstream of G-
protein-coupled receptors (GPCRs).  Studies have shown that mice expressing a modified Gαo 
protein that is insensitive to modulation by RGS proteins (RGSi Gαo) have reduced sensitivity to 
heat stimuli due to enhanced signaling at the mu-opioid receptor (MOPR).  In contrast, 
preliminary data suggest these mice have a hyperalgesic response to mechanical stimulation.  
The goal of the present study was to determine the mechanism behind this hypersensitivity to 
mechanical stimuli using the von Frey test.  Behavioral testing was performed following 
injection of antagonists which we believed would affect von Frey responding, namely 
antagonists of the opioid receptors and the nociception/Orphanin FQ (N/OFQ) receptor (NOPR). 
The baseline hyperalgesic phenotype in the RGSi Gαo mice was reversed by pretreatment with 
systemic or central administration of the NOPR selective antagonist J-113397, while the opioid 
antagonist naltrexone further intensified the hyperalgesic phenotype.  In contrast J-113397 
pretreatment did not affect behavior on the 52C hot plate test in either wild type or RGSi Gαo 
mice.  Intraplantar injection of λ-carrageenan produced an inflammatory hyperalgesia in the von 
Frey test which was also reversed by J-113397.  Whole brain homogenates from RGSi Gαo 
knock-in mice had unchanged levels of NOPR as determined by [3H]N/OFQ saturation binding 




activate G-protein as measured by [35S]GTPγS uptake stimulation.  Together, the results are 
consistent with increased signaling downstream of NOPR leading to a hyperalgesic phenotype in 
the RGSi Gαo knock-in mice, while increased signaling downstream of MOPR produces a 
protective effect against NOPR-mediated hyperalgesia.  Similar opposing actions of the systems 
are seen in inflammatory hyperalgesia in wild-type mice, suggesting that in both cases the 
balance between MOPR and NOPR signaling is disturbed.  
 
Introduction 
Regulator of G-protein signaling (RGS) proteins comprise a family of approximately 30 
members characterized by a RH domain or RGS box. 20+ members of the RGS family have 
GTPase accelerating protein (GAP) activity and promote inactivation of the heterotrimeric G-
protein complex following G-protein-coupled receptor (GPCR) activation (Watson et al., 1996).  
They do so by binding to the active GTP-bound Gα subunit and accelerating the conversion to an 
inactive GDP bound state (De Vries et al., 1995; Berman et al., 1996).  This allows the Gα and 
βγ proteins making up the heterotrimer to reform, thereby negatively regulating signaling (De 
Vries et al., 2000).  Thus, alteration of RGS protein levels can change GPCR signaling in vitro. 
RGS proteins have some degree of selectivity for certain Gα subtypes (Talbot et al., 2010), or 
even for specific GPCRs (Wang and Traynor 2013). In spite of this, different RGS protein 
subtypes likely have a considerable amount of functional redundancy.  Therefore, attempts to 
understand RGS function by knocking out individual RGS proteins in vivo have often failed to 
uncover the expected phenotype (Doupnik 2015). However, a single base mutation of a 
conserved glycine (183 or 184) in Gα to serine prevents the RGS-Gα interaction (see figure 0.2; 
Tesmer et al., 1997) and renders the Gα protein RGS-insensitive (RGSi).  RGSi Gα-proteins are 
powerful tools to study the impact of RGS proteins in vivo, as these mutant proteins allow us to 
remove all endogenous RGS GAP activity at a particular G-protein and thus to investigate the 
impact of RGS proteins, even when the cognate RGS protein is not known  
The mu opioid receptor (MOPR) is a member of the superfamily of 7-transmembrane domain 
GPCRs and as such is sensitive to the action of RGS proteins.  Signaling downstream of MOPR 
is enhanced when coupled to RGSi Gαo proteins in vitro (Clark et al., 2003, 2004 and 2005).  In 




thermal stimuli due to enhanced signaling downstream of MOPR (Lamberts et al., 2013).  
However, in contrast to these data with heat as the nociceptive stimulus, our preliminary studies 
suggested that RGSi Gαo knock-in mice are more sensitive to mechanical stimuli.  We 
hypothesized this was due to an overactive pronociceptive system, enhanced by the RGS Gαo 
knock-in, that is working against the antinociceptive opioid system.  Many other Gαo-coupled 
receptors can regulate the perception of pain, and therefore may contribute to the observed 
phenotype in RGSi Gαo mice.  Prime amongst these is the 17-amino acid nociceptin peptide (also 
known as Orphanin FQ or N/OFQ) which has been reported to have either pro or anti-
nociceptive effects depending on specific testing conditions.  The N/OFQ receptor (NOPR) is a 
Gαi/o coupled GPCR with high expression throughout the brain and spinal cord (Mogil and 
Pasternak 2001), and there are data suggesting that RGS proteins can affect NOPR signaling in 
vitro (Xie et al., 2005; Wang and Traynor 2013).  NOPR is classified as a fourth member of the 
opioid receptor family due to its close sequence homology with the classical opioid receptors 
(Mollereau et al., 1994), although it is insensitive to the opioid antagonists naltrexone and 
naloxone.  Administration of NOPR agonists directly to the brain consistently produces 
hyperalgesic effects in rodent models (Meunier et al., 1995; Citterio et al., 2000; Bytner et al., 
2001).  Furthermore, NOPR antagonists reverse hyperalgesia induced by various methods 
including carrageenan injection, spinal nerve ligation, chronic constriction injury and single 
prolonged stress (Mabuchi et al., 2003; Suyama et al., 2003; Scoto et al., 2009; Zhang et al., 
2012).  Alongside these behavioral findings, a number of reports have suggested that expression 
of both NOPR and N/OFQ increase during periods of hyperalgesia (Gabriel et al., 2004; Joseph 
et al., 2007; Zhang et al., 2012).  The extended upregulation of NOPR and its endogenous 
peptide during periods of hyperalgesia coupled with the ability of NOPR antagonists to relieve 
these states further suggests this system may be involved in the maintenance of hyperalgesia.   
A substantial body of data suggest that the NOPR and MOPR systems interact at a systems level, 
with NOPR activity in general providing anti-opioid effects (Bertorelli et al., 1999; Khroyan et 
al., 2009).  Therefore, we decided to investigate how the RGSi Gαo knock-in protein affects the 
activity of NOPR and the interaction between the MOPR and NOPR systems in vivo.  We 
hypothesized that these systems would counteract each other, such that increased NOPR activity 





Materials and Methods 
Transgenic mice.  Heterozygous RGSi Gαo knock-in mice were generated as described 
previously (Fu et al., 2004; Fu et al., 2006; Huang et al., 2006; Goldenstein et al., 2009) then 
backcrossed for 6 generations onto a 129S1/SvImJ background.  Animals for experimentation 
were obtained by breeding a heterozygous RGSi Gαo knock-in mouse with a wild type mouse 
from this same background.  Heterozygous animals (+/GS) and wild types (WT) were obtained 
at the expected 50:50 Mendelian ratio using this method.  All animals used in the described 
experiments were obtained using this breeding scheme, including experiments using only wild 
type animals.  Animals homozygous for the RGSi Gαo knock-in protein typically die shortly after 
birth and therefore were not used in any of the experiments described in this report.   
Heterozygous Gαo knock-out mice were generated as described previously (Mortensen et al., 
1992; Sowell et al., 1997; Duan et al., 2007) and backcrossed for at least 10 generations onto a 
C57BL/6 background.  Animals for experimentation were obtained by breeding heterozygous 
Gαo knock-out mice with wild type mice from the same background.  Heterozygous (+/-) and 
wild type (WT) animals were obtained at the expected 50:50 Mendelian ratio.  Homozygous 
mice were not used as they are rarely produced and do not survive weaning. 
Both male and female mice were used for the described experiments, and animals were typically 
between 8 and 16 wk of age at time of experiment and typically weighed between 18 and 25 g. 
Animals were group housed, segregated by sex, with no more than five animals per cage and had 
access to food and water ad libitum.  Animals were maintained on a 12-hour light/dark cycle 
with lights turning on at 0700 each day.  All testing occurred during the 12-hour light phase.  
Studies were performed in accordance with the Guide for the Care and Use of Laboratory 
Animals established by the National Institutes of Health and all experimental protocols were 
approved by the University of Michigan Committee on the Use and Care of Animals. 
Mechanical Sensitivity (von Frey test).  Animals were placed in a custom-built apparatus 
consisting of a series of self-contained clear Plexiglas boxes with open tops and a wire mesh 
floor (9x18x18 cm).  Animals were allowed to acclimate for at least 30 min before the start of 
testing.  Calibrated von Frey filaments (North Coast Medical, Gilroy CA) with 0.16 g, 0.4 g, 0.6 
g, 1.0 g, 1.4 g, 2.0 g, 4.0 g, and 6.0 g strengths were used for all experiments. The ascending 




Briefly, each filament was applied with gradually increasing force perpendicular to the plantar 
surface of the hind paw until it bent, then was held in place for 2-3 s or until the animal withdrew 
its paw.  Each filament was applied 3 times to each hind paw.  Withdrawal threshold was defined 
as the first filament that caused the animal to withdraw its paw on at least 2 of the 3 applications 
of a particular filament. The 6.0 g strength filament was considered the maximal cutoff as this 
filament would lift the animal’s paw before bending in most cases.  A baseline measurement was 
obtained for each animal before experimental treatment.  Measurements from both hind paws 
were averaged except in experiments involving intraplantar λ-carrageenan injections in which 
case each paw was analyzed separately. 
Thermal Sensitivity.  The hot plate test was used to measure reactivity to a thermal nociceptive 
stimulus.  A hot plate analgesia meter (Columbus Instruments International Corporation, 
Columbus OH) was maintained at 52.0 C +/- 0.2 C.  The mouse was gently placed within an 
open top clear Plexiglas enclosure on the surface of the hot-plate and the latency to lick 
forepaws, shake a hind paw or jump off the surface of the hot plate was recorded.  Mice were 
removed from the hot plate immediately after responding.  Mice that did not respond within 60 s 
were immediately removed from the surface of the hot plate to prevent tissue damage.  Two 
baseline measurements separated by 30 min were obtained from each animal before experimental 
treatment.  Experimental results were recorded 30 min after drug or vehicle treatment. 
Injections.  For experiments involving intraplantar (i.pl.) injections powdered λ-carrageenan was 
dissolved in a solution containing 10% ethanol, 10% alkamuls, and 80% sterile water to obtain a 
2.5% λ-carrageenan solution.  20 μl of this solution was injected into the plantar surface of one 
hind paw, with administration to left and right paws counterbalanced between animals. A 30 G 
needle tip was used for injection.  Injections were administered slowly over 10-20 s to prevent 
leakage from the injection site.  Animals were returned to their home cage following λ-
carrageenan administration and monitored daily for any signs of distress, then sacrificed 
immediately after the conclusion of the experiment. 
Intraperitoneal (i.p.) injections were administered in a 10 ml/kg volume based on animal body 
weights obtained the same day.  A 30 G needle tip was used for injection.  Experimental testing 




Prior to intracerebroventricular (i.c.v.) injections mice were anesthetized in a drop-jar containing 
0.2 ml of isoflurane on a gauze pad.  Mice were removed from the drop-jar when breathing 
slowed to approximately one breath per second.  Depth of anesthesia was then confirmed by hind 
paw pinch.  A 26 G needle tip was used for injection.  i.c.v. injections were administered in a 5 
μl volume over a period of two minutes. Needle tip was held in the i.c.v. space for 1 min 
following injection.  Immediately following experiment animals were again anesthetized and a 
second i.c.v. injection containing Fast-Green dye was administered into the original i.c.v. 
injection site.  Animals were then sacrificed by cervical dislocation followed by decapitation, 
and the brain was dissected.  Animals in which dye was not present throughout the i.c.v. space 
were excluded from the study. 
Membrane preparation.  Mice were sacrificed by cervical dislocation followed by decapitation 
immediately before tissue preparation.  The whole brain except for olfactory bulbs was removed 
and immediately placed in 3 ml of ice cold 50 mM tris buffer pH 7.4 then prepared as described 
previously (Lester and Traynor 2006).  Membrane protein concentration was determined using a 
BCA assay kit (Thermo Scientific, Rockford, IL). 
[3H]N/OFQ saturation binding assay.  Whole brain membrane homogenates (100 μg 
membrane protein per well) were incubated in a 50 mM pH 7.4 Tris buffer with various 
concentrations of tritiated N/OFQ peptide ([3H]N/OFQ). Total assay volume was 200 μl in each 
well, and each condition was performed in duplicate. For each concentration of [3H]N/OFQ non-
specific binding was determined by addition of the NOPR antagonist J-113397 at 50 μM.  Assay 
was allowed to incubate for 60 min at room temperature (25°C). Assay was then terminated by 
rapid filtration through a GF/C filter (Whatman) using a MLR-24 harvester (Brandel, 
Gaithersburg, MD) and bound radioactivity was measured by scintillation counting using a 
Wallac 1450 MicroBeta counter (PerkinElmer, Waltham, MA) as described previously 
(Lamberts et al., 2013). 
N/OFQ stimulated [35S]GTPγS binding.  Whole brain membrane homogenates (100 μg 
membrane protein per well) were added to [35S]GTPγS-binding buffer (50 mM Tris, 5 mM 
MgCl2, 100 mM NaCl, and 1 mM EDTA, pH 7.4, with 2 mM dithiothreitol, 30 μM GDP, and 0.4 
U/ml adenosine deaminase) with various concentrations of N/OFQ. 0.1 nM [35S]GTPγS was then 




rapid filtration through a GF/C filter and bound radioactivity was measured by liquid scintillation 
counting as described previously (Lamberts et al., 2013). Total assay volume was 200 μl per well 
and each condition was performed in triplicate. 
Statistical Analysis.  Experiments involving two independent treatments, and experiments 
involving both a genetic and a treatment variable were analyzed using 2-way analysis of variance 
(2-way ANOVA) followed by Tukey’s post-hoc test for multiple comparisons.  The Ro64-6198 
dose/response experiment was analyzed using 1-way analysis of variance (1-way ANOVA) 
followed by Holm-Sidak's multiple comparisons test.  The i.c.v. J-113397 time course 
experiment was analyzed using 3-way analysis of variance (3-way ANOVA), with time, 
genotype and treatment factors.  If statistics for a main effect, interaction or post-hoc comparison 
are not detailed in the results these effects did not reach significance.  Experiments with only two 
conditions were analyzed using Student's t-test.  P<0.05 was the predetermined threshold for 
significance in all experiments. For ex vivo binding experiments Bmax and Kd were determined 
using a one-site saturation binding curve (Hill slope = 1), while EC50 was determined using an 
agonist versus response curve (Hill slope = 1) as described previously (Lamberts et al., 2013). 
 
Results 
Heterozygous RGSi Gαo knock-in mouse hyperalgesic behaviors 
Heterozygous RGSi Gαo knock-in mice were used for this study because the full knock-in mice 
are not viable (Lamberts et al., 2013).  The heterozygous RGSi Gαo knock-in mice were shown 
to be significantly more sensitive to mechanical stimuli than their wild-type littermates as 
measured using von Frey filaments. (Fig. 4.1A). This baseline hyperalgesic behavior in the RGSi 
Gαo mice was fully reversed by the NOPR antagonist J-113397 (3.2 mg/kg i.p.) without affecting 
withdrawal threshold in wild-type littermates (Fig. 4.1B).  Two-way ANOVA revealed 
significant main effects of treatment (F(1,23)=4.467, p=0.0456), genotype (F(1,23)=18.23, 
p=0.0003), and genotype x treatment interaction (F(1,23)=10.82, p=0.0032).  This same dose of J-
113397 administered i.p. did not affect latency to respond on the hot plate test in heterozygous 
RGSi Gαo mice or their wild type littermates (Fig. 4.1C).  Two-way ANOVA revealed 




p=0.4877) or genotype x treatment interaction (F(1,20)=0.4415, p=0.5140).  In contrast, the opioid 
antagonist naltrexone administered i.p. to heterozygous RGSi Gαo knock-in mice further reduced 
their baseline hyperalgesic withdrawal threshold while this same treatment did not affect 
withdrawal threshold of wild-type littermates (Fig. 4.1D).  Two-way ANOVA revealed 
significant main effects of genotype (F(1,25)=41.62, p<0.0001), and treatment (F(1,25)=6.922, 
p=0.0144).  
Fig. 4.1: (A) Baseline mechanical nociceptive threshold in heterozygous RGSi Gαo knock-in mice (+/GS) 
compared to wild type (WT) littermates (von Frey test; **P< .01, compared to wild type littermates; unpaired 
t-test).  (B) Effect of NOPR antagonist J-113397 pretreatment on mechanical nociceptive threshold in 
heterozygous RGSi Gαo knock-in mice and wild type littermates (von Frey test; **P<0.01, compared to RGSi 
Gαo knock-in mice administered vehicle; significant main effects of genotype, treatment and interaction; 2-
way ANOVA followed by Tukey’s post-hoc test). (C) Effect of NOPR antagonist J-113397 pretreatment on 
latency to respond to a thermal nociceptive stimulus in heterozygous RGSi Gαo knock-in mice and wild type 
littermates (hot plate test; significant main effect of genotype; 2-way ANOVA followed by Tukey’s post-hoc 
test). (D) Effect of naltrexone pretreatment on mechanical nociceptive threshold in heterozygous RGSi Gαo 
knock-in mice and wild type littermates (von Frey; *P<0.05, compared to RGSi Gαo knock-in mice 
administered saline; significant main effects of genotype and treatment; 2-way ANOVA followed by Tukey’s 






To confirm a role for NOPR in the hyperalgesic behavior the NOPR partial agonist Ro64-6198 
was administered systemically to wild type animals. This produced a bi-phasic pattern of 
behavior with reduced withdrawal threshold at 1.0 mg/kg but not at 3.2 mg/kg (Fig. 4.2A).  One-
way ANOVA revealed a significant main effect of treatment (F(5,30)=4.867, p=0.0022).  A 
reduction in spontaneous locomotion (or sedative effect) which may explain the biphasic nature 
of the response was observed following the 3.2 mg/kg dose.  Although this locomotor effect was 
not quantified in our study, locomotor disruption at this dose of Ro64-6198 in mice is consistent 
with previously published results (Chang et al., 2015).  The hyperalgesic behavior caused by 1.0 
mg/kg Ro64-6198 was fully reversed by 3.2 mg/kg of the NOPR antagonist J-113397 
administered i.p. (Fig. 4.2B).  This dose of J-113397 did not affect withdrawal threshold when 
administered to animals injected with Ro64-6198 vehicle.  Two-way ANOVA revealed a 




Fig. 4.2: (A) Effect of NOPR agonist Ro64-6198 on mechanical nociceptive threshold in wild type mice (von 
Frey test).  Data are expressed as mean ± S.E.M. n = 6 mice for each dose.  (*P<0.05, compared to vehicle 
treated animals; significant main effect of treatment; 1-way ANOVA followed by Holm-Sidak's post-hoc test).  
(B) Effect of NOPR antagonist J-113397 on mechanical hyperalgesia produced by NOPR agonist Ro64-6198 
compared to animals administered vehicle. Data are expressed as mean ± S.E.M. n = 6 mice per group 
(*P<0.05, compared to animals administered Ro64-6198 plus vehicle (J-113397); significant main effect of J-





Finally, to examine if the hyperalgesic effect was dependent on central NOPR activity we 
administered 10 μg of the NOPR antagonist J-113397 intracerebrovetricularly (i.c.v.).  This 
produced a reversal of the heterozygous RGSi Gαo baseline hyperalgesic phenotype that lasted 
for at least 60 min without affecting withdrawal threshold in wild type mice (Fig. 4.3).  In the 
time course experiment (Fig. 4.3A) three-way ANOVA revealed significant main effects of time 
(F(3,3)=22.95, p<0.0001), genotype (F(1,3)=35.92, p<0.0001), and genotype x treatment interaction 
(F(1,3)=5.141, p=0.0246).  At the 30 min time point (Fig. 4.3B) two-way ANOVA revealed a 
significant main effect of treatment (F(1,46)=5.132, p=0.0282).  
Hyperalgesia caused by intra-plantar λ-carrageenan injection is attenuated by systemic 
administration of a NOPR antagonist in both wild type and RGSi Gαo mice 
λ-Carrageenan (20 μl of 2.5% solution) administered into the plantar surface of one hind paw 72 
hr before testing produced a hyperalgesic effect in wild type mice. When these animals were pre-
treated with the NOPR antagonist J-113397 at 3.2 mg/kg i.p. 30 min before testing they no 
longer displayed this hyperalgesic behavior (Fig. 4.4A).  J-113397 did not affect withdrawal 
threshold in the contralateral hind paw of these animals (Fig. 4.4A).  Two-way ANOVA revealed  
Fig. 4.3: (A) Effect of NOPR antagonist J-113397 delivered intracerebroventricularly (i.c.v.) on mechanical 
nociceptive threshold in heterozygous RGSi Gαo knock-in mice (+/GS) and wild type (WT) littermates (von 
Frey test; significant main effects of time, genotype, and genotype vs. treatment interaction; 3-way ANOVA).  
Data are expressed as mean ± S.E.M. n = 6-7 mice per group.  (B) 30-minute timepoint from Figure 4.3A (von 
Frey test; *P<0.05, compared to +/GS animals administered vehicle; significant main effect of treatment; 2-way 







Fig 4.4: (A) Effect of NOPR antagonist J-113397 pretreatment on mechanical hyperalgesia produced by intraplantar 
administration of a 2.5% λ-carrageenan solution given 72 hours before testing in wild type mice (von Frey test; **P<0.01, 
compared to the control paw of vehicle treated animals; significant main effects of J-113397 and λ-carrageenan treatments; 2-way 
ANOVA followed by Tukey’s post-hoc test).  (B) Effect of NOPR antagonist J-113397 pretreatment on mechanical hyperalgesia 
produced by intraplantar administration of a 2.5% λ-carrageenan solution given 72 hours before testing in in heterozygous RGSi 
Gαo knock-in mice (von Frey test; significant main effects of J-113397 and λ-carrageenan treatments; 2-way ANOVA followed 
by Tukey’s post-hoc test).  (C) Effect of naltrexone pretreatment (30 min) on mechanical hyperalgesia produced by intraplantar 
administration of a 2.5% λ-carrageenan solution given 7 days before testing in wild type mice (von Frey test; *P<0.05, compared 
to the control paw of naltrexone treated animals; significant main effect of λ-carrageenan treatment; 2-way ANOVA followed by 
Tukey’s post-hoc test).  (D) Effect of naltrexone pretreatment (30 min) on mechanical hyperalgesia produced by intraplantar 
administration of a 2.5% λ-carrageenan solution given 7 days before testing in heterozygous RGSi Gαo mice (von Frey test; 
*P<0.05, compared to the control paw of naltrexone treated animals; significant main effect of λ-carrageenan treatment; 2-way 






significant main effects of J-113397 treatment (F(1,20)=5.561, p=0.0287), and carrageenan 
injection (F(1,20)=8.818, p=0.0076).  Heterozygous RGSi Gαo mice treated with λ-carrageenan 
and administered 3.2 mg/kg J-113397 showed a similar hyperalgesic response and reversal by J-
113398, but post-hoc effects did not reach significance (Fig. 4.4B).  Two-way ANOVA revealed 
significant main effects of J-113397 treatment (F(1,20)=7.91, p=0.0108), and carrageenan injection 
(F(1,20)=5.196, p=0.0337).  Mice with λ-carrageenan injected paws were no longer significantly 
hyperalgesic 7 days after carrageenan administration. This was true for both wild type (Fig. 
4.4C) and heterozygous RGSi Gαo mice (Fig. 4.4D).  However, injection of naltrexone (10 
mg/kg i.p.) at this time point causes the carrageenan injected paw to show a re-occurrence of 
increased sensitivity to von Frey filaments in both wild type (Fig. 4.4C) and heterozygous RGSi 
Gαo mice (Fig. 4.4D) without affecting sensitivity of the non-carrageenan injected paw. In wild 
type mice injected with naltrexone (Fig. 4.4C) two-way ANOVA revealed a significant main 
effect of carrageenan injection (F(1,20)=6.843, p=0.0165).   In RGSi Gαo mice injected with 
naltrexone (Fig. 4.4D) two-way ANOVA revealed a significant main effect of carrageenan 
injection (F(1,20)=10.28, p=0.0044). 
NOPR expression level and potency of N/OFQ to stimulate G-protein is unchanged in RGSi 
Gαo mice 
MOPR receptor numbers and G-protein activation by MOPR agonist is not changed in brain 
homogenates from the RGSi Gαo mice compared to their wild-type littermates (Lamberts et al., 
2013).  To determine if the integrity of the NOPR system was similarly maintained between the 
genotypes, we evaluated [3H]N/OFQ binding and stimulation of [35S]GTPγS binding in whole 
brain membrane homogenates prepared from wild type mice and heterozygous RGSi Gαo 
littermates (Fig. 4.5).  There was no change in the Bmax (110 +/- 14 vs. 120 +/- 18 fmol/mG-
protein) or affinity (0.58 +/- 0.19 v 0.77 +/- 0.27 nM) of N/OFQ or in the EC50 (2.8 +/- 1.6 vs. 
1.6 +/- 0.69 nM) or maximal effect of N/OFQ to stimulate [35S]GTPγS binding (Table 4.1). 
Effect of the NOPR agonist Ro64-6198 in Gαo knockout animals 
 To confirm a role for Gαo in the actions of NOPR activation, we tested the activity of the NOPR 
agonist Ro64-6198 in mice with a 50% reduction in Gαo expression. Note that as stated 
previously the complete Gαo knockout animals are not viable (Lamberts et al., 2013).  These 




4.6). Two-way ANOVA revealed a significant main effect of treatment (F(1,20)=11.711, 
p=0.0027).   
Table 4.1: [3H]N/OFQ saturation binding and potency of [35S]GTPγS uptake stimulation by N/OFQ. 
 
  
 WT +/GS 
[35S]GTPγS stimulation   
EC50 (nM) 2.9 ± 1.6 1.6 ± 0.69 
R2 0.85 0.86 
Saturation Binding   
Bmax (fmol/mg) 110 ± 14 120 ± 18 
Kd (nM) 0.58 ± 0.19 0.77 ± 0.28 
R2 0.79 0.86 
B 
Fig 4.5: Stimulation of [35S]GTPγS binding by N/OFQ in whole brain membrane homogenates from heterozygous 
RGSi Gαo knock-in mice (+/GS) and wild type (WT) littermates (A) and comparison of [3H]-N/OFQ saturation 
binding in whole brain membrane homogenates from wild type (WT) mice and heterozygous RGSi Gαo knock-in 
(+/GS) littermates (B).  Non-linear fit of [N/OFQ] vs. [35S]GTPγS uptake was used to determine the EC50 of 
N/OFQ potency (see Table 4.1).  Non-linear fit of [N/OFQ] vs. specific N/OFQ binding was used to determine 
Bmax and Kd (see Table 4.1).  Unpaired t-tests used to compare EC50, Kd and Bmax between RGSi Gαo knock-in 
and wild type animal's whole brain membranes, no significant differences.  Data presented are representative 
experiments selected from n = 3 independent experiments performed in duplicate over the entire listed 
concentration range.  Data are expressed as mean ± S.E.M for each concentration tested.  Each experiment used 






The results described demonstrate that in a mouse model loss of RGS control at the 
heterotrimeric Gα protein Gαo produces a hyperalgesic behavioral phenotype in response to a 
mechanical stimulus.  This contrasts with the MOPR-mediated antinociceptive behavioral 
phenotype in these mice as measured by the hot plate and tail withdrawal tests (Lamberts et al, 
2013).  The increased responding to mechanical nociceptors in the mutant mice was fully 
reversed by the NOPR antagonist J-113397 given systemically or i.c.v. suggesting that 
overactive signaling downstream of 
NOPR within the central nervous 
system is responsible for the observed 
behavior.  Opioid receptor blockade by 
naloxone worsened the hyperalgesia.  
Carrageenan-induced mechanical 
hyperalgesia was also reversed by J-
113397.   These findings indicate that 
in wild type mice there is a fine balance 
between the pronociceptive activity of 
NOPR and the antinociceptive activity 
of the opioid systems that is altered by 
increasing Gαo signaling, via loss of 
RGS control, or by inflammation.  
The finding that the NOPR antagonist J-113397 given i.c.v. reverses the behavioral phenotype 
indicates a central location as the source of the hyperalgesia in the RGSi Gαo knock-in mice. 
This is consistent with many published findings that supraspinal administration of a NOPR 
agonist produces pronociceptive effects (reviewed in Lambert, 2008; Schroder et al., 2014; 
Kiguchi et al., 2016) and that N/OFQ itself administered i.c.v. induces hyperalgesia (Zhu et al., 
1997).  Moreover, i.c.v. administration of a NOPR antagonist peptide derivative (UFP-101) 
provides an antinociceptive action in the mouse formalin test (Rizzi et al., 2006) and UFP-101 
injected directly into the periaqueductal gray (PAG) reverses carrageenan-induced mechanical 
allodynia and chronic constriction tactile allodynia in rats (Scoto et al., 2009).  These data 
indicate that, as in the RGSi Gαo knock-in mouse model, the NOPR system is constitutively 
Fig 4.6: Effect of NOPR agonist Ro64-6198 on mechanical 
nociceptive threshold in heterozygous Gαo knock-out (+/-) 
mice and wild type (+/+) littermates (von Frey test; *P<0.05, 
compared to vehicle treated wild type animals.  Significant 
main effect of Ro64; 2-way ANOVA followed by Tukey’s 
post-hoc test). Data are expressed as mean ± S.E.M. n = 6 




active (Kiguchi et al., 2016) and that the PAG is a potential locus of this activity.  The PAG has 
high levels of NOPR (Neal et al., 1999; Mollereau and Mouledous 2000) and N/OFQ (Houtani et 
al., 1996).  Moreover, in the PAG N/OFQ inhibits presynaptic GABA release onto a subset of 
PAG neurons but increases an inwardly rectifying K+ conductance (GIRK) in all neurons, 
thereby inhibiting descending PAG output (Vaughan et al., 1997).  Thus, the antinociceptive 
action of morphine given in the PAG, measured by the tail flick assay, is reversed by intra-PAG 
injection of N/OFQ (Morgan et al., 1997).   
In support of a role for increased NOPR signaling in the RGSi Gαo hyperalgesic phenotype we 
observed that peripheral administration of the brain-penetrant, NOPR selective agonist Ro64-
6198 produced a hyperalgesic response in wild-type mice that was fully reversed by the NOPR 
antagonist J-113397.  Similarly, hyperalgesia produced by i.pl. injection of λ-carrageenan was 
fully reversed by J-113397 in wild type mice.  This NOPR antagonist significantly attenuated the 
more severe hyperalgesic response in RGSi Gαo knock-in mice given carrageenan, while the 
opioid antagonist naloxone tended to make the hyperalgesia more severe. These data are 
consistent with observations of increased circulating N/OFQ in various rodent models of 
hyperalgesia, suggesting that increased NOPR activity may be a general feature during 
hyperalgesic states (Joseph et al., 2007; Zhang et al., 2012).  
On the other hand, these findings contrast with reports that peptidic NOPR agonists administered 
directly to peripheral sites can produce antinociception (Sakurada et al., 2005) and that systemic 
non-peptide NOPR agonists attenuate models of inflammatory bowel disease (Sobczak et al., 
2014).  Moreover, mice lacking NOPR or N/OFQ exhibit increased inflammatory hyperalgesia 
(Depner et al., 2003).  A considerable amount of data also show that spinal administration of 
NOPR agonists results in antinociception in acute pain models and antihyperalgesic and 
antiallodynic actions during chronic pain (for review see Kiguchi et al., 2016).  Data such as 
these have been used to suggest that NOPR agonists may have therapeutic potential for the 
treatment of inflammatory pain.  However, our current findings and others support the notion 
that NOPR’s effects on pain are highly variable (Lambert 2008; Schroder et al., 2014; Kiguchi et 
al., 2016) and depend on the pain modality, source of pain, whether there are compensatory 




The fact that loss of RGS regulation of Gαo enhances the signaling downstream of NOPR is 
evidence that Gαo plays a major role in NOPR and well as MOPR signaling.  This is not 
surprising given the abundance of this Gα protein in the brain and its importance for transduction 
of signaling via many Gαo-coupled GPCRs (Birnbaumer et al., 2001).  The behavioral phenotype 
we observed in the RGSi-Gαo mice occurred without changes in brain NOPR expression or the 
ability of N/OFQ to stimulate G-protein.  Our previous results show that there is no significant 
difference in protein expression of Gαz, Gαi1, Gαi2, Gαi3, Gβ1-4, or Gγ2 in either the brain or 
spinal cord of RGSi Gαo knock-in mice compared to wild type controls, suggesting that the 
behavioral changes are due to increased signaling downstream of G-protein activation rather than 
compensatory changes in other G-proteins (Lamberts et al., 2013).  The mice do however have a 
slight reduction in Gαo protein expression in both the brain and the spinal cord (~25% reduction 
compared to wild type littermates), likely as a compensatory response to the increased signaling 
activity of the knock-in protein (Lamberts et al., 2013).  This may lead to an underestimate of the 
level of signaling enhancement caused by loss of RGS control, although the reduction of Gαo 
expression was not sufficient to reduce the maximal stimulation of G-protein activity by N/OFQ 
in brain tissue, suggesting that there is more than sufficient Gαo coupled to NOPR even in the 
heterozygotes.  In support of this we found the NOPR agonist Ro64-6198 produced the same 
degree of hyperalgesia in mice with a 50% reduction in Gαo expression, showing that there is 
more than sufficient Gαo available for efficient NOPR signaling and that the minor reduction of 
Gαo in the RGSi Gαo mice is likely insignificant to the behavioral phenotype.   
Our previous results indicating that removal of RGS control at Gαo may reduce sensitivity to 
painful stimuli in a MOPR dependent manner led us to speculate that RGS proteins might 
provide a target for analgesic drug development (Lamberts et al, 2013).  Other evidence supports 
this, for example, intrathecal administration of an RGS4 inhibitor produces an antinociceptive 
effect and enhances the action of the MOPR ligand DAMGO in the formalin test in the mouse 
(Yoon et al., 2015).  However, this must now be tempered with the knowledge that in some 
situations the pronociceptive effects of increased NOPR signaling may predominate.  
Nonetheless, rather than a pan inhibition of all RGS protein activity as seen in the RGSi Gαo 
genetic model, our present and previous findings suggest it is feasible that selectively targeting 
specific members of the RGS protein family will produce useful analgesic effects.  There are 




several target Gαo; however, there are reports that RGS proteins show selectivity for particular 
receptors (Ghavami et al., 2003; Wang et al., 2011; Xie and Palmer 2007).  Most RGS proteins 
have not been thoroughly investigated for their ability to differentially regulate MOPR and 
NOPR signaling, although RGS19 has been reported to act at MOPR but not NOPR in SH-SY5Y 
cells (Wang and Traynor 2013) suggesting that RGS19 may be a suitable target.  On the other 
hand, overexpression studies indicate RGS19 can act as a GAP for NOPR (Xie et al., 2005).  
Due to these contradictory findings, more work is needed to determine suitable RGS proteins 
which regulate MOPR, but not NOPR signaling. 
In conclusion, the finding that the RGSi Gαo mice show hyperalgesic behavior towards a 
mechanical stimulus is in stark contrast to the opioid receptor dependent antinociceptive 
phenotype seen in the hot-plate and tail withdrawal tests (Lamberts et al., 2013).  We saw no 
effect of the NOPR antagonist J-113397 on the baseline increased latency in the hot-plate test.  
However, we did observe that the hyperalgesia in the RGSi Gαo mice was prevented by J-113397 
and made worse by the addition of the opioid antagonist naloxone, with similar observations 
during λ-carrageenan-mediated inflammation.  These data show that the MOPR and NOPR 
systems are working in opposition, but that the pronociceptive action of NOPR signaling 
predominates in hyperalgesic states. This serves to highlight a fine homeostatic balance between 
the two systems that in some situations have opposing actions on pain perception.   
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The work described in this thesis investigates the role of the regulator of G-protein signaling 
(RGS) proteins in pain and depression, using RGS insensitive (RGSi) Gα proteins.  Chapters 1 
and 2 cover the role of RGS proteins in depression and depressive-like behaviors with a focus on 
the serotonin 1A receptor (5-HT1AR), while chapters 3 and 4 describe the involvement of RGS 
proteins in pain and antinociceptive effects with a focus on the interaction between the mu opioid 
receptor (MOPR) and nociceptin receptor (NOPR).  Using mice expressing either RGSi Gαi2 or 
RGSi Gαo this work highlights substantial differences between the intracellular signaling 
processes that affect antidepressant-like and hyperalgesic responses downstream of these 
receptors.  Therefore, I have broken this discussion chapter into two sections, one summarizing 
the findings involving 5-HT1AR-mediated antidepressant-like effect, and the other on the 
interplay between MOPR and NOPR in hyperalgesic responses. 
 
5-HT1AR-Mediated Antidepressant-Like Behaviors 
Work described here shows that RGSi Gαi2 knock-in mice have spontaneous antidepressant-like 
behavior that is reversible not only by systemic injection of a 5-HT1AR antagonist (WAY100-
635; Talbot et al., 2010) but also by intra-hippocampal injection of the same antagonist (Fig. 
2.1).  This 5-HT1AR dependent phenotype is not due to an upregulation of 5-HT1AR expression 
(Fig. 2.5A) nor changes in hippocampal G-protein expression (Fig. 2.5B).  The 5-HT1AR 
dependent phenotype of these animals (i.e. increased antidepressant-like but not hypothermic 
effects of 5-HT1AR agonists; Talbot et al., 2010) is mimicked by intra-hippocampal 
administration of a 5-HT1AR agonist (8-OH-DPAT), which produces antidepressant-like effects 




Together these data show that hippocampal 5-HT1AR activity is necessary for the expression of 
antidepressant-like behavior in the RGSi Gαi2 knock-in mouse in the tail suspension test, and that 
activating this same receptor population in wild type mice is sufficient to mimic this behavior. 
The lack of hypothermic effects following intra-hippocampal 5-HT1AR agonist was unsurprising 
as 5-HT1AR-mediated hypothermia is known to depend on 5-HT1AR expressed on serotonergic 
neurons in the raphe nucleus (Goodwin et al., 1987; Higgens et al., 1988; Hillegaart 1991).  This 
supports the hypothesis that the RGSi Gαi2 knock-in mouse has enhanced activity downstream of 
post-synaptic 5-HT1AR (e.g. in the hippocampus) but not pre-synaptic 5-HT1AR in the raphe 
nuclei (Fig. 5.1) which would produce hypothermia as well as inhibit antidepressant-like effects 
due to reduced serotonin release.  Based on these results we predict that other pre-synaptic 5-
HT1AR-mediated effects (e.g. reduced extracellular 5-HT concentrations throughout the brain) 
would similarly be unaltered by the RGSi Gαi2 mutation, although this has not yet been tested.  
It’s possible that 5-HT1A autoreceptor responses have a relatively high receptor reserve and thus 
loss of RGS control is unable to further increase these responses, however the fact that i.p. 8-
Fig. 5.1: Diagram of brain 5-HT network.  Serotonergic cells originating in the dorsal 
and median raphe nuclei exhibit a slow constant firing rate that is inhibited by activation 
of the 5-HT autoreceptors (e.g. 5-HT1AR).  Serotonergic axons project into areas such as 
the hippocampus where any of the 14 5-HT receptors may be activated by 5-HT released 





OH-DPAT produced a dose dependent hypothermia in wild type mice (Fig 2.2B) and 
heterozygous littermates (Talbot et al., 2010) suggests that this response can be enhanced further 
by increased receptor activation, but loss of RGS control at Gαi2 fails to do so. 
We also show that the 5-HT1AR agonist 8-OH-DPAT has a greater hyperpolarizing effect on 
CA1 hippocampal neurons from heterozygous RGSi Gαi2 knock-in mice compared to wild type 
littermates (Fig. 2.3A-D).  This involves a reduction in spontaneous action potentials and resting 
membrane potential, as well as an increase in the minimal current injection required to produce 
an action potential (rheobase) in neurons from heterozygous RGSi Gαi2 knock-in mice after 8-
OH-DPAT application (Fig. 2.3F).  There was no significant change in these measures in wild 
type mice, although we expect higher doses of 8-OH-DPAT would be effective (Fig. 2.3E).  The 
increased ability for 8-OH-DPAT to reduce resting membrane potential and spontaneous 
neuronal firing (as well as increase rheobase) in neurons from heterozygous RGSi Gαi2 knock-in 
mice supports the hypothesis that hippocampal neurons from these mice are more sensitive to the 
effects of 5-HT1AR agonists.  Going forward we propose a next step would be to record from 
raphe nuclei neurons to test the hypothesis that the RGSi Gαi2 mutation preferentially affects 
post-synaptic 5-HT1AR compared to pre-synaptic receptors in the raphe. 
After identifying the hippocampus as a relevant locus of action for 5-HT1AR-mediated 
antidepressant-like effects, we next attempted to determine relevant RGS proteins that could be 
inhibited in this region to produce antidepressant-like effects.  We set out to inhibit RGS19 due 
to its known regulation of hippocampal 5-HT1AR in both in vitro and ex vivo models (Wang et 
al., 2014), as well as relatively high hippocampal expression compared to any other brain region 
(Grafstein-Dunn et al., 2001).  As no highly selective RGS19 inhibitors are available we used the 
RGS4/19 inhibitor CCG-203769, which inhibits RGS4/19 with over 100x increased potency 
compared to other RGS proteins examined (Blazer et al., 2015).  Although acute intra-
hippocampal injection of CCG-203769 did not produce antidepressant-like effects, repeated 
administration surprisingly produced antidepressant-like effects only in female animals (Fig 
2.4A).  This sex difference was not explained by compensatory changes in RGS19 protein 
expression (Fig 2.4C) or sensitivity to the antidepressant-like effects of 5-HT1AR agonist 




including that this inhibitor has more potent actions in female animals, or that different RGS 
proteins are involved in the antidepressant-like response in male mice.   
While the tail suspension test experiments with CCG-203769 produced promising results 
suggesting that an RGS inhibitor could produce antidepressant-like effects through a 
hippocampal action, these studies did not conclusively identify the mechanism of action by 
which CCG-203769 produced these effects.  Therefore, in the future we hope to characterize the 
effects of intra-hippocampal CCG-203769 in mice lacking either RGS4 or RGS19.  To 
accomplish this RGS4 knockout mice can be used as the homozygous knockout animals are 
viable and overall healthy (Dripps et al., 2017).  Although RGS19 knockout mice have now been 
generated by Crispr Cas9 technology and are commercially available 
(https://www.jax.org/strain/030071), these animals have not been characterized and the 
homozygous knockouts may not be appropriate for behavioral experiments, either due to health 
issues or behavioral abnormalities (e.g. locomotor dysfunction) that would complicate 
interpretation of CCG-203769’s effects.  Considering that RGS4 knockout mice do not have a 
baseline antidepressant-like phenotype (Dripps et al., 2017), and that RGS19 is known to 
regulate the effect of 5-HT1AR receptor agonists in hippocampal neurons (Wang et al., 2014), 
we predict that CCG-203769 will be equally effective in RGS4 knockout mice as in wild type 
controls, while CCG-203769 will not produce antidepressant-like effects in RGS19 knockout 
mice (assuming these animals are appropriate for behavioral testing).  It is possible that RGS19 
knockout mice will display spontaneous antidepressant-like behavior without drug treatment, in 
which case we would not expect CCG-203769 treatment to produce further antidepressant-like 
effects.   
If the RGS19 knockout mice have a very robust antidepressant-like phenotype at baseline, then it 
may not be possible to produce further antidepressant-like effects in these animals.  In this case 
the basis of their antidepressant-like phenotype can instead be probed.  We would expect an 
RGS19 knockout mouse antidepressant-like phenotype to be dependent on hippocampal 5-
HT1AR receptor activity, such that either systemic or intra-hippocampal 5-HT1AR antagonist 
administration should reverse their antidepressant-like behavior, similar to the results obtained 
with RGSi Gαi2 knock-in animals.  Furthermore, we would predict that similar signaling changes 




knockout mice, including increased phosphorylation of GSK3β (Talbot et al., 2010) and an 
increased hyperpolarizing effect of 5-HT1AR agonists on hippocampal neurons. 
In addition to working with the knockout mice, RGS4 and RGS19 can be knocked down in the 
hippocampus using intra-hippocampal delivery of lentivirus expressing shRNA against either 
RGS protein.  While this strategy will produce a much more localized reduction of RGS protein 
this will provide valuable information on how these RGS proteins affect antidepressant-like 
behavior.  We expect that hippocampal knockdown of RGS19, but not RGS4, would produce 
antidepressant-like behaviors.  Furthermore, RGS4 knockdown would not affect the 
antidepressant-like behavior produced by intra-hippocampal CCG-203769.  As lentiviral protein 
knockdown in brain tissues does not always remove 100% of the target protein, sufficient 
RGS19 protein may remain available for CCG-203769 to inhibit and produce additional 
antidepressant-like effects.  In either case, we expect the effects of hippocampal RGS19 
knockdown to depend on 5-HT1AR receptor activity, and to produce similar changes in 
signaling downstream of hippocampal 5-HT1AR receptors as observed in the RGSi Gαi2 knock-
in mice. 
It is possible that neither knockdown of RGS4 or RGS19 will produce antidepressant-like 
effects.  In this case other RGS proteins that CCG-203769 targets less potently (RGS7, RGS8; 
Blazer et al., 2015) and are expressed at high levels in the hippocampus (Gold et al., 1997; 
Grafstein-Dunn et al., 2001) can be knocked down as well.  If these RGS proteins all inhibit 5-
HT1AR signaling in the hippocampus to some degree then only knocking down these proteins 
together would mimic the effects of CCG-203769 and the RGSi Gαi2 phenotype, and would 
suggest a considerable redundancy exists between these RGS proteins for this response.  In this 
case lentivirus delivering shRNA against all four of these RGS proteins can be used. 
While we were surprised to observe a sex difference in the antidepressant-like effects of CCG-
203769, and this difference was not explainable by differential RGS19 expression or sensitivity 
to 5-HT1AR agonists, we hope to explore the basis of this sex difference further.  One possibility 
is that female mice are more sensitive to the antidepressant-like effects of CCG-203769 than 
male mice, and that higher doses would produce antidepressant-like effects in male mice as well.  
Unfortunately, intra-hippocampal administration of CCG-203769 above 3 μg produced catatonia 




catatonia occurs due to off target effects, and that other RGS inhibitors would not produce such 
side effects.  In this case other RGS inhibitors tested at a wider dose range could identify potency 
differences between male and female animals.  The use of newer RGS inhibitors would also help 
to validate the results obtained with CCG-203769, and may aid in narrowing down the relevant 
mechanism of action.  For example, if intra-hippocampal delivery of any RGS inhibitor with 
activity at RGS19 produces antidepressant-like effects in female animals, while inhibitors 
lacking RGS19 activity did not, then this would bolster the evidence that hippocampal RGS19 
plays a critical role in this behavior. 
Rather than a drug specific sensitivity difference, female mice may be more sensitive to the 
effects of hippocampal RGS protein knockdown in general.  In this case intra-hippocampal 
lentiviral delivery of shRNA against the RGS proteins both expressed in the hippocampus and 
targeted by CCG-203769 (RGS4, RGS7, RGS8, RGS19) may also produce differential effects 
between male and female animals.  This would suggest that there is enhanced downstream 
signaling effects (e.g. increased MAPK or GSK3β phosphorylation) in the hippocampus of 
female animals compared to male animals following RGS inhibition.  A general increased 
sensitivity to RGS inhibition in female animals would be surprising however, as no sex 
differences were reported in the phenotype of RGSi Gαi2 knock-in mice (Talbot et al., 2010), 
although the possibility remains that CCG-203769 is affecting behavior through signaling 
pathways that do not depend on Gαi2.  It is also possible that the estrous cycle plays a role in the 
observed sex difference, and if so sensitivity to the antidepressant-like effects of CCG-203769 
may be altered in animals at different stages of the cycle.   
Finally, we compared the antidepressant-like phenotype of the RGSi Gαi2 knock-in mice to the 
behavior of RGSi Gαo knock-in mice.  Heterozygous RGSi Gαo knock-in mice also display 
antidepressant-like behavior, however in contrast to RGSi Gαi2 knock-in mice this behavior is 
not reversed by 5-HT1AR antagonist pretreatment (Fig. 2.6).  This suggests that while loss of 
RGS control at either G-protein produces antidepressant-like effects, it does so through distinct 
mechanisms.  Although the receptors involved in the RGSi Gαo antidepressant-like phenotype 
have not been thoroughly investigated at this time, these mice are known to have an enhanced 
antidepressant-like response to the DOPR agonist SNC80 on the tail suspension test (personal 




antidepressant-like effects in wild type animals (Jutkiewicz et al., 2005; Dripps et al., 2017). 
Therefore, we hypothesize that increased DOPR activity in RGSi Gαo knock-in mice produces an 
antidepressant-like phenotype such that DOPR antagonist pretreatment should reverse this 
behavior. 
 
Opioid Receptor-Mediated Hyperalgesic Behaviors 
Based on a previous report showing that heterozygous RGSi Gαo knock-in mice have a complex 
phenotype related to pain perception, including increased sensitivity to opioid analgesics on the 
hot plate test and decreased sensitivity on the tail withdrawal test (Lamberts et al., 2013), we set 
out to determine the behavior of these animals in response to a mechanical nociceptive stimulus 
as measured using von Frey filaments.  Based on their baseline antinociceptive behavior in both 
the hot plate and tail withdrawal tests we hypothesized that these animals would have a baseline 
antinociceptive response on the von Frey test as well.  Heterozygous RGSi Gαo knock-in mice 
surprisingly had a baseline hyperalgesic response on the von Frey test (Fig. 4.1A) that was 
reversed by pretreatment with the NOPR antagonist J-113397 (Fig. 4.1B).  As all previous 
results suggest that these animals have increased activity of opioid receptor systems, we next set 
out to test the effects of the opioid antagonist naltrexone on the observed hyperalgesic behavior.  
Naltrexone increased the hyperalgesic behavior in the RGSi Gαo knock-in mice even further 
without affecting wild type behavior (Fig 4.1D).  We also show that the blood brain barrier 
permeable NOPR partial agonist Ro64-6198 (Dautzenberg et al., 2001) administered 
systemically produces a hyperalgesic response in wild type mice on the von Frey test (Fig. 4.2A-
B).  This suggests that increased activity downstream of NOPR in RGSi Gαo knock-in mice 
counteracts the antinociceptive effects of opioid receptor activity in these animals.  This 
behavioral phenotype was not due to increased NOPR expression in the brain, nor an increased 
ability of the endogenous peptide ligand for NOPR (N/OFQ) to stimulate G-protein (Fig. 4.5A-
B) suggesting that signaling changes downstream of Gαo due to the loss of RGS control drive this 
behavior. 
In addition, we show that i.c.v. administration of the NOPR antagonist J-113397 also reverses 
the RGSi Gαo knock-in mouse hyperalgesia (Fig 4.3A and B), suggesting a central locus for this 




nociceptive and anti-opioid activity when delivered i.c.v. (Mogil et al., 1996a; Mogil et al., 
1996b) or directly into the periaqueductal gray (PAG) (Morgan et al., 1997).  We therefore 
hypothesize that increased sensitivity to endogenous nociceptin peptide in the PAG of RGSi Gαo 
mice produces a pro-nociceptive response that should be reversible by specific delivery of a 
NOPR antagonist to the PAG.  This should be examined in future studies. 
As the RGSi Gαo knock-in mice had an opioid antagonist reversible antinociceptive phenotype 
on the hot plate test (Lamberts et al., 2013), and opioid receptor and NOPR activity appear to 
produce opposing effects on the von Frey test, we set out to determine whether a NOPR 
antagonist would have a similar pro-nociceptive effect on the hot plate test in these animals.  The 
NOPR antagonist J-113397 did not affect hot plate responding in either wild type or RGSi Gαo 
knock-in mice (Fig 4.1C), consistent with published results showing this antagonist does not 
affect behavior on the hot plate test in wild type mice (Ozaki et al., 2000).  This suggests that 
while the opioid receptors and NOPR have a push/pull effect on pain threshold in response to a 
mechanical stimulus (von Frey test) leading to an overall hyperalgesic phenotype in RGSi Gαo 
knock-in mice, in response to a thermal stimulus (hot plate test) only the antinociceptive action 
of opioid receptor activity appears to contribute to the phenotype.  We expect that NOPR 
antagonist treatment will similarly fail to affect RGSi Gαo knock-in mouse behavior on the tail 
withdrawal test as well, and preliminary results support this hypothesis (Fig. 5.2).  
We next sought to determine whether this 
push/pull phenomenon between the NOPR 
and opioid systems observed in the RGSi Gαo 
knock-in mouse model also occurs during a 
model of inflammatory hyperalgesia.  
Intraplantar λ-carrageenan injection produced 
a hyperalgesic response on the von Frey test 
that was alleviated by NOPR antagonist 
pretreatment 72 hr after carrageenan injection 
(Fig. 4.4A and B).  In a pilot experiment 
naltrexone administered 72 hr after 
carrageenan administration did not make 
Fig. 5.2: Pilot 50C warm water tail withdrawal test 
results in wild type (WT) and heterozygous RGSi Gαo 
knock-in mice (+/GS) treated with NOPR antagonist J-




hyperalgesia significantly worse (data not shown).  Seven days following carrageenan 
administration mice were no longer significantly hyperalgesic, however naltrexone 
administration caused the carrageenan injected paw to again become hyperalgesic (Fig. 4.4C and 
D).  Combined with the lack of effect of these antagonists on healthy wild type mice shown 
earlier (Fig. 4.1B and D) this suggests that both NOPR and opioid receptor activity increases 
during inflammatory states, either due to constitutive activity (Corder et al., 2013), or increased 
opioid peptide release, and that this increased (non-NOPR) opioid receptor activity contributes to 
the apparent recovery of hyperalgesia at later time points.   
Naltrexone and naloxone have shown the ability to reverse recovery from hyperalgesic states in 
other models as well, including human post-operative hyperalgesia (Koppert et al., 2003), human 
electrically induced hyperalgesia (Koppert et al., 2005), hyperalgesia after plantar incision in 
mice (Campillo et al., 2011) and mouse complete Freund's adjuvant (CFA) induced 
inflammatory hyperalgesia (Corder et al., 2013).  The finding that MOPR expression increases in 
the dorsal root ganglia (DRG) during inflammatory injury (Ji et al., 1995; Endres-Becker et al., 
2007) may provide an explanation for the ability of opioid antagonists to reverse recovery from 
hyperalgesia, as opioid antagonist application would counteract the antihyperalgesic effects of 
MOPR upregulation.   
Prepronociceptin (the precursor peptide to the endogenous peptide ligand for NOPR) mRNA also 
increases in a subpopulation of neurons in the DRG following intraplantar carrageenan 
administration (Andoh et al., 1997; Itoh et al., 2001).  Interestingly the increase in 
prepronociceptin occurred as soon as 30 minutes after carrageenan injury (Andoh et al., 1997) 
while MOPR expression changes did not reach a maximal level until 3 days after injury (Ji et al., 
1995).  These results suggest that endogenous ligands acting at MOPR and NOPR in the DRG 
may be driving the changes in nociceptive threshold observed following carrageenan injury.  It is 
possible that increased activity downstream of MOPR and NOPR in the DRG also occurs in the 
RGSi Gαo knock-in mice, contributing to a phenotype that resembles carrageenan injury on the 
von Frey test.  Although our results showing that i.c.v. administration of a NOPR antagonist 
reverses hyperalgesia in RGSi Gαo knock-in mice (Fig. 4.3A) suggest that NOPR activity in the 
brain is required for the expression of this behavior, it is possible that a pathway involving both 




could alleviate their hyperalgesia.  We 
hope to test this hypothesis by 
administering NOPR and MOPR 
antagonists i.t. and comparing their 
effects to systemic administration of the 
same antagonists, both in inflammatory 
hyperalgesia models and in the RGSi 
Gαo knock-in mice.  
We also wanted to determine a role for 
other Gα proteins in the hyperalgesic 
activity.  RGSi Gαi2 knock-in mice were 
not significantly hyperalgesic compared 
to wild type littermates in a pilot experiment (Fig. 5.3) although there was a slight trend towards 
hyperalgesia.  This suggests that removing RGS control downstream of Gαo promotes 
hyperalgesia to a greater degree than removing RGS control downstream of Gαi2, and that Gαo is 
the primary G-protein involved in this NOPR dependent behavior.  This hypothesis should be 
tested more fully in the future.  If a full study shows that RGSi Gαi2 knock-in mice are 
significantly hyperalgesic antagonist studies will provide information on the receptor systems 
involved in this behavior.  
While behavioral results on the von Frey test suggest that RGSi Gαo knock-in mice have 
enhanced activity of the NOPR system, this enhancement has not been conclusively 
demonstrated at a signaling level.  In a pilot experiment the NOPR agonist Ro64-6198 was 
administered i.p. to wild type and heterozygous RGSi Gαo knock-in mice followed 15 minutes 
later by brain dissection and processing of whole brain tissue for Western blot analysis.  Whole 
brain tissue was analyzed for preliminary studies as relevant brain regions have not yet been 
determined for this behavior.  The phosphorylation state of MAPK was analyzed as NOPR 
expressing cells exhibit increased MAPK phosphorylation following NOPR agonist treatment in 
vitro (Zhang 2012), and stimulation of MAPK activity by Gαi/o proteins is well characterized 
(see Belcheva and Coscia 2002 for review).  Unexpectedly, vehicle treated RGSi Gαo knock-in 
mice appeared to have reduced MAPK activity, and Ro64-6198 further reduced activity in RGSi 
Fig. 5.3: Pilot von Frey test results in wild type (WT) and 
heterozygous RGSi Gαi2 knock-in mice (+/GS) treated with 




Gαo knock-in mice but not wild type littermates (Fig. 5.4), although the Ro-64-6198 effect did 
not reach significance.  Two-way ANOVA revealed a significant main effect of genotype 
(F(1,8)=6.845, p=0.0308).  In the future, it should be determined whether the decreased MAPK 
activity in the brains of heterozygous RGSi Gαo knock-in mice is consistent enough to reach 
significance with repeated experimentation, and if so whether that decrease is reversible by 
NOPR antagonist pretreatment.  This would suggest that the observed decrease in MAPK 
activity is in fact due to increased baseline NOPR activity in these animals, while a failure to 
reverse this difference with a NOPR antagonist would indicate that one of the many other 
GPCRs signaling through Gαo may be reducing MAPK activity instead.  
While the decrease in MAPK activity was 
unexpected, this may reflect a network effect 
whereby increased NOPR action on some 
neurons does produce increased MAPK 
activity in those cells (as predicted by in 
vitro models), but due to downstream effects 
on other neurons the net effect is a reduction 
in MAPK activity.  A similar process has 
been observed in the hippocampus of 
animals treated systemically with the 5-
HT1AR agonist 8-OH-DPAT, where a 
decrease in MAPK activity is observed 
instead of the expected increase due to 
network effects downstream of the direct site 
of action (Chen et al., 2002).  If a similar 
process is occurring in the brains of RGSi Gαo knock-in mice following NOPR agonist treatment 
then we might expect to see regional differences in MAPK activity following agonist 
administration, similar to the differential results across brain regions with 5-HT1AR agonists 
(Chen et al., 2002).  Direct versus indirect effects of NOPR agonists on central MAPK activity 
across brain regions could then be distinguished by comparing the effects of ex vivo NOPR 
agonist application to primary neurons or brain slices from various regions with high NOPR 
expression and relevance to antinociceptive action such as the periaqueductal gray (PAG) or 
Fig. 5.4: MAPK activity (quantified as ratio of 
pERK/total ERK) in whole brain homogenates from 
heterozygous RGSi Gαo knock-in mice (+/GS) and wild 
type (WT) littermates administered Ro64-6198 or 
vehicle i.p. (Significant main effect of genotype, no 
significant post-hoc effects; 2-way ANOVA followed 




striatum (Calo’ et al., 2000).   A more detailed level of signaling information could prove useful 
for determining the brain regions involved in the RGSi Gαo behavioral phenotype.   
Once relevant brain regions are identified NOPR/opioid antagonist microinjections can be 
performed in those regions to determine how more specific regional receptor blockade affects the 
behavior of these animals.  Furthermore, the relevant RGS proteins expressed in each region can 
be identified, with the aim of inhibiting/knocking down RGS proteins that would normally 
inhibit Gαo.  This would allow testing of 
the hypothesis that specific RGS protein 
knockdown/inhibition in relevant brain 
regions can mimic the RGSi Gαo 
behavioral phenotype, providing novel 
information on how RGS proteins 
control pain perception.   
Current work which suggests that RGSi 
Gαo knock-in mice have an enhanced 
antinociceptive response to endogenous 
opioid peptides on thermal tests should 
also be extended.  The initial behavioral 
screening of these animals revealed a 
naloxone reversible antinociceptive 
phenotype on both the hot plate and tail 
withdrawal tests (Lamberts et al., 2013).  
I have extended these results to show 
that RGSi Gαo knock-in mice have an 
enhanced response to the enkephalinase 
inhibitor RB101 (Fig. 5.5A and B) 
supporting the hypothesis that 
endogenous opioids produce increased 
antinociception in these animals.  In wild 
type mice (Fig. 5.5A) two-way ANOVA 
A 
B 
Fig. 5.5: Effects of 50 μg enkephalinase inhibitor RB-101 
administered i.c.v. (A) in wild type and (B) heterozygous 
RGSi Gαo knock-in mice (*** indicates 10-minute vehicle 
treated animals are significantly different from both 10-
minute 50ug RB-101 and 10-minute 50ug RB-101 + NTX 
treated animals; 2-way ANOVA followed by Tukey’s post-




revealed a significant main effects of time (F(3,32)=9.781, p<0.0001).  In RGSi Gαo knock-in mice 
(Fig. 5.5B) two-way ANOVA revealed significant main effects of time (F(3,52)=14.44, p<0.0001), 
and treatment x time interaction (F(6,52)=4.98, p=0.0004).  Furthermore, preliminary data suggest 
that these animals also exhibit increased swim stress induced antinociception (Fig. 5.6A and B) 
although these results did not reach significance.  The development of opioid antinociceptive 
tolerance should be determined in these animals compared to wild types (Fig. 5.7) in order to 
determine whether the RGSi Gαo mutation enhances opioid antinociception selectively, or 
whether the development of tolerance is increased as well.  
B A 
C D 
Fig. 5.6: Effects of a 15-minute swim stress in room temperature water on 52C hot plate test responding before 
and after 10 mg.kg i.p. naloxone (A) in wild type and (B) heterozygous RGSi Gαo knock-in mice (n = 5-9). (C) 
Effect of 15-minute swim stress in room temperature water on von Frey responding in wild type mice (n = 4). 
(D) Effect of 15-minute swim stress in room temperature water on von Frey responding in wild type mice 3 




Swim stress induced antinociception is a 
naloxone reversible antinociceptive 
response thought to occur due to the 
release of endogenous opioid peptides 
following a brief forced swim in room 
temperature water (Mogil et al., 1996c), 
and so we expected this response to 
increase in RGSi Gαo knock-in mice.  
When initially piloting this experiment, 
we were able to produce a robust 
antinociceptive response in wild type mice 
on a C57/Bl6 background following a 15-
minute swim stress (data not shown), 
however wild type mice on a 129 background did not have a significant antinociceptive response 
to this same procedure on either the hot plate test (Fig. 5.6A) or von Frey test (Fig. 5.6C).  In 
order to eliminate the possibility that a ceiling effect was preventing the presentation of swim 
stress induced antinociception on the von Frey test we next tested the effects of a 15 min swim 
stress 3 hr after intra-plantar λ-carrageenan injection in wild type animals (Fig. 5.6D) and still 
did not detect a swim stress induced antinociception.  Nonetheless, compared to the total lack of 
response in wild type animals heterozygous RGSi Gαo knock-in mice appeared to have a slight 
swim stress induced antinociception on the hot plate that was reversed by NLX pretreatment 
(Fig. 5.6C), but these effects did not reach significance.  
The lack of a swim stress induced antinociception in wild type mice on a 129 background may 
be due to a tonically active stress response during behavioral testing which precludes further 
stress induced responses in this strain of mice.  These animals are especially prone to freezing 
while being handled compared to other strains (personal observation), a known response to fear 
in rodent models (Curzon et al., 2009).  In addition, in the elevated plus maze test for anxiety 
wild type 129 mice have a low baseline time spent in open arms (~4.5% of total test time vs. 
~10% for C57/Bl6 mice; Fig. 5.8; Komada et al., 2008) suggesting that wild type 129 strain mice 
may be anxiogenic at baseline.  A thorough study of 16 different mouse strains found marked 
differences in behavior between strains, with BALB/cJ mice spending the most time in open 
Fig. 5.7: Pilot study of tolerance to morphine challenge 
one week after morphine pellet implantation in the flank 




arms and A/J mice spending the least (Trullas and Skolnick 1993).  Although 129 strain mice 
were not one of the 16 strains compared, our results (~4.5% of time spent in open arms; Fig. 5.8) 
would make 129 mice one of the most anxiogenic strain out of the 16 tested (Trullas and 
Skolnick 1993).  As the RGSi Gαo knock-in mice are also available on a C57/Bl6 background 
this experiment should be repeated in the future using C57/Bl6 background RGSi Gαo knock-in 
mice instead of 129 background mice to produce a more robust swim stress induced 
antinociception.  On this background strain we expect to see a clear naloxone reversible swim 
stress induced antinociception in wild type animals on both the hot plate and von Frey tests 
(either with or without carrageenan), with even greater swim stress induced antinociception 
observed in C57/Bl6 background RGSi Gαo knock-in mice.  This would support the hypothesis 
that RGSi Gαo knock-in mice are not only more sensitive to the antinociceptive effects of 
exogenous opioid agonists, but to endogenous opioid peptide release as well. 
The elevated plus maze experiment was 
initially run to determine whether other 
NOPR dependent behaviors unrelated 
to pain response are altered in RGSi 
Gαo knock-in mice.  Centrally acting 
NOPR agonists are known to produce 
anxiolytic effects on the elevated plus 
maze (Gavioli et al., 2008), and so we 
predicted that RGSi Gαo knock-in mice 
would similarly have an anxiolytic 
phenotype on this test.  RGSi Gαo 
knock-in mouse have no apparent 
behavioral differences compared to 
wild type littermates on the elevated plus maze (Fig. 5.8), although the time spent in open arms 
for wild type 129 mice is already so low (~4.5% of test duration) that if the RGSi Gαo knock-in 
mouse instead have an anxiogenic phenotype we may not be able to detect it using this test.  This 
low baseline should allow us to study the anxiolytic effects of NOPR agonists however, and this 
response has already been well characterized on the elevated plus maze in wild type animals 
treated systemically with Ro64-6198 (Dautzenberg et al., 2001; Jenck et al., 2000; Wichman et 
Fig. 5.8: 15-minute elevated plus maze results with wild 
type (WT) and heterozygous RGSi Gαo knock-in mice 
(+/GS) following i.p. saline administration( n = 5).  
Average time for a C57/Bl6 mouse on this test with these 
conditions often exceeds 150 s (personal communication 




al., 2000).  We predict that Ro64-6198 will promote anxiolytic behavior more potently in RGSi 
Gαo knock-in mice compared to wild type controls.  Alternatively, RGSi Gαo may differentially 
affect different NOPR-mediated behaviors, such that its pronociceptive action is enhanced while 
anxiolytic activity is unaffected.  If this is the case then Ro64-6198 should produce anxiolytic 
effects with similar potency in both the mutant mice and wild type littermates.  This line of 
experimentation would allow us to determine whether NOPR dependent hyperalgesic and 
anxiolytic effects can be separated by promoting activity downstream of one G-protein compared 
to others, and if so whether potential therapeutics targeting NOPR can separate these effects. 
 
Conclusions 
The results with RGSi Gαi2 knock-in mice could have important implications for the treatment of 
depression, as they appear to achieve a long-standing goal within this field of research: to 
promote signaling downstream of postsynaptic 5-HT1AR receptors without stimulating 
presynaptic 5-HT1AR receptor activity.  This could lead to antidepressant drugs acting at new 
targets (such as RGS19) with improved effects compared to the current generation of 
antidepressant drugs. 
The RGSi Gαo knock-in mouse results provide novel insight into the interplay between opioid 
and NOPR systems, but the observation of hyperalgesic behavior in these animals must temper 
our enthusiasm for any novel treatment strategy that will increase signaling downstream of the 
NOPR/Gαo complex.  At the same time, the results suggesting that these animals have an 
antidepressant-like phenotype through a yet-to-be determined mechanism should be explored 
further, as it remains possible that the antidepressant-like and hyperalgesic effects could be 
separated.   
Together these results demonstrate the value of using RGSi G-protein knock-in mouse models to 
study complex behaviors.  These models can reveal differences between closely related G-
proteins, aid in identifying RGS proteins relevant to therapeutic responses, and increase our 
knowledge of how various receptor systems interact.  This information has the potential to 
uncover new therapeutic targets, and has already improved our understanding of antidepressant 
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